Filamentous fungal strains containing mutations and genetic modifications that enhance protein productivity and methods thereof
By genetically modifying filamentous fungi, particularly by replacing threonine at amino acid position 813 of the LOV protein with lysine, the protein production rate of filamentous fungi was improved, solving the problem of insufficient protein production in existing technologies and making it suitable for commercial protein production through deep culture.
Patent Information
- Application Number
- CN201980049956.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-07-30
- Filing Date
- 2019-07-25
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-07-25
AI Technical Summary
In the current technology, the protein production rate of filamentous fungi has not reached a satisfactory level, making it difficult to meet the needs of large-scale commercial applications.
Protein production can be improved by genetically modifying filamentous fungi, particularly by altering the amino acid sequence of LOV proteins, such as replacing threonine (T) with lysine (K) at position 813.
This technology improves protein production from filamentous fungi, making it suitable for large-scale commercial protein production in deep culture and increasing protein yield.
Smart Images

Figure CN112654704B_ABST
Abstract
Description
Technical Field
[0001] The present disclosure generally relates to the fields of biology, genetics, molecular biology, filamentous fungi, industrial protein production, etc. More particularly, the strains of the present invention and the methods of the present disclosure relate to genetic modifications in filamentous fungi that produce variant strains of filamentous fungi that comprise a protein productivity-enhancing phenotype. More specifically, as presented, described and illustrated herein, such variant strains of filamentous fungi that comprise a protein productivity-enhancing phenotype are well suited for growth in submerged culture, such as for large-scale production of target proteins for commercial applications.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 711,846, filed on July 30, 2018, which is hereby incorporated by reference in its entirety.
[0004] References to sequence listings
[0005] The electronically submitted content of the text file sequence listing named "NB41504-WO-PCT_SequenceListing.txt" was created on July 24, 2019 and is 160KB in size, which is hereby incorporated by reference in its entirety. Background Art
[0006] Filamentous fungi (e.g., Aspergillus species, Penicillium species, Talaromyces species, Fusarium species, Myceliophthora species, Neurospora species, Trichoderma species, etc.) are capable of expressing high levels of native (endogenous) and heterologous proteins, making them very suitable for large-scale production of proteins (e.g., enzymes) and / or metabolites for industrial and / or commercial applications, such as pharmaceutical applications, animal health applications, food applications, beverage applications, etc. Filamentous fungi are typically grown in submerged cultures of mycelium in bioreactors (fermenters) that are regulated to introduce and distribute oxygen and nutrients into the culture medium (i.e., culture broth). For example, the filamentous fungus Trichoderma reesei / T. reesei (the asexual form of the fungus Hypocrea jecorina) is known to be an efficient producer of cellulases (see, e.g., PCT International Publication Nos. WO 1998 / 15619, WO 2005 / 028636, WO 2006 / 074005, WO 1992 / 06221, WO 1992 / 06209, WO 1992 / 06183, and WO 2002 / 12465).
[0007] Therefore, filamentous fungi are utilized due to their ability to produce proteins that are valuable in the production of commodities such as cellulose (derived) ethanol, textile products, grain products, detergents, fibers, food additives, feed additives, etc. For example, recombinant gene expression in such fungal host strains is a common method for producing proteins (i.e., for industrial and commercial purposes), and therefore, improvements in protein productivity of fungal host strains are an important economic factor in protein production costs. Therefore, as will be appreciated by those skilled in the art, such compositions and methods for improving protein production in filamentous fungal strains have important commercial significance.
[0008] As described herein, the present disclosure generally relates to genetically modified filamentous fungal strains comprising an improved / increased protein productivity phenotype, which addresses such persistent and unmet needs in the art. Summary of the invention
[0009] Described herein are strains, cells, methods, constructs, etc. related to filamentous fungi having an increased protein productivity phenotype. Accordingly, certain embodiments of the present disclosure relate to modified Ascomycota cells derived from a parent cell, wherein the modified cell comprises a polynucleotide sequence encoding a variant LOV protein having at least 50% sequence identity to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18 and comprising a lysine (K) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO: 4, wherein the modified cell comprises an increased protein productivity phenotype relative to the parent cell, e.g., when fermented / cultured under the same conditions. In certain embodiments, the parent cell contains a wild-type polynucleotide sequence encoding a native LOV protein, which has at least 50% sequence identity with SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 or SEQ ID NO:18 and contains a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0010] In related embodiments, the fungal cell further comprises a heterologous polynucleotide encoding a protein of interest (POI). In other embodiments, the cell further comprises a polynucleotide encoding the NIK1 (M743T) protein of SEQ ID NO: 19. In certain other embodiments, the modified cell further comprises at least one genetic modification that deletes, disrupts or reduces the expression / production of a protein selected from the group consisting of MPG1 SFB3, SEB1, CRZ1, TSP2, SSB7 and GAS1.
[0011] In other embodiments, the Ascomycete cell is selected from Trichoderma species, Aspergillus species, Fusarium species, Penicillium species, Candida species, Chrysosporium species, Cephalosporium species, Talaromyces species, Neurospora species, and Myceliophthora species.
[0012] Thus, in certain embodiments, the parent Aspergillus species cell contains a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO:11 or SEQ ID NO:18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0013] In another embodiment, the parental Penicillium species cell comprises a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO: 12 or SEQ ID NO: 18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO: 2. In other embodiments, the parental Talaromyces species cell comprises a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO: 13 or SEQ ID NO: 18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO: 2.
[0014] In another embodiment, the parental Fusarium species cell contains a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO:14 or SEQ ID NO:18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0015] In certain other embodiments, the parental Myceliophthora species cell contains a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO:15 or SEQ ID NO:18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0016] In other embodiments, the parental Neurospora species cell contains a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO: 16 or SEQ ID NO: 18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0017] In another embodiment, the parental Candida species cell contains a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO:17 or SEQ ID NO:18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0018] In certain other embodiments, the parental Trichoderma species cell contains a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO:2 or SEQ ID NO:18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0019] In other embodiments, the protein of interest is produced by and purified from the modified cells of the disclosure.
[0020] In other embodiments, the present disclosure relates to a modified Ascomycota cell derived from a parent cell comprising a wild-type polynucleotide sequence that hybridizes under stringent hybridization conditions to a nucleic acid sequence encoding a native LOV protein of SEQ ID NO:2, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18, and the native LOV protein comprises a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2, wherein the modified cell comprises a modified polynucleotide sequence that hybridizes under stringent hybridization conditions to a nucleic acid sequence encoding a LOV protein of SEQ ID NO:2, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18, and the LOV protein comprises a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2. The amino acid sequence position of position 813 of NO:4 comprises a lysine (K) residue. In certain embodiments, the cell further comprises a heterologous polynucleotide encoding a protein of interest. In another embodiment, the cell further comprises a polynucleotide construct encoding the NIK1 (M743T) protein of SEQ ID NO:19. In other embodiments, the cell further comprises at least one genetic modification that deletes, destroys or reduces the expression / production of a protein selected from the group consisting of MPG1 SFB3, SEB1, CRZ1, TSP2, SSB7 and GAS1.
[0021] In certain other embodiments, the Ascomycota cell is selected from Trichoderma species, Aspergillus species, Fusarium species, Penicillium species, Candida species, Chrysosporium species, Cephalosporium species, Talaromyces species, Neurospora species, and Myceliophthora species.
[0022] In certain embodiments, the parent Aspergillus species cell contains a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO:11 or SEQ ID NO:18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0023] In other embodiments, the parent Penicillium species cell contains a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO:12 or SEQ ID NO:18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0024] In another embodiment, the parental Tularemella species cell contains a polynucleotide sequence encoding a natural LOV protein, which has at least 50% sequence identity with SEQ ID NO:13 or SEQ ID NO:18 and contains a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0025] In certain other embodiments, the parental Fusarium species cell contains a polynucleotide sequence encoding a native LOV protein, which has at least 50% sequence identity with SEQ ID NO:14 or SEQ ID NO:18 and contains a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0026] In another embodiment, the parental Myceliophthora species cell contains a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO:15 or SEQ ID NO:18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0027] In other embodiments, the parental Neurospora species cell contains a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO: 16 or SEQ ID NO: 18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0028] In certain other embodiments, the parental Candida species cell comprises a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO: 17 or SEQ ID NO: 18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2.
[0029] In other embodiments, the parent Trichoderma sp. cell comprises a polynucleotide sequence encoding a native LOV protein having at least 50% sequence identity to SEQ ID NO: 2 or SEQ ID NO: 18 and comprising a threonine (T) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO: 2. Other embodiments relate to proteins of interest produced by the modified cells of the present disclosure.
[0030] Certain other embodiments of the present disclosure relate to a vector comprising a polynucleotide encoding a variant LOV protein, wherein the variant LOV protein has at least 50% sequence identity with SEQ ID NO:2, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 or SEQ ID NO:18 and comprises a lysine (K) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:4.
[0031] In other embodiments, the present disclosure relates to a polynucleotide encoding a variant LOV protein, wherein the variant LOV protein has at least 50% sequence identity with SEQ ID NO:2, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 or SEQ ID NO:18 and comprises a lysine (K) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:4.
[0032] In another embodiment, the present disclosure relates to a polynucleotide encoding a variant LOV protein, wherein the polynucleotide encoding the variant protein hybridizes with a nucleic acid sequence encoding a LOV protein of SEQ ID NO:2, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 or SEQID NO:18 under stringent hybridization conditions, and the LOV protein comprises a lysine (K) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:4.
[0033] In other embodiments, the present disclosure relates to a mutant Trichoderma strain derived from a parent strain, wherein the mutant strain comprises a gene encoding a LOV variant protein having at least 50% sequence identity to SEQ ID NO:4 or SEQ ID NO:18 and comprising a lysine (K) residue at a sequence position corresponding to position 813 of SEQ ID NO:4. In certain embodiments, the mutant strain comprises an increased protein productivity phenotype relative to the parent strain. In other embodiments, the mutant strain further comprises a polynucleotide construct encoding the NIK1 (M743T) protein of SEQ ID NO:19. In other embodiments, the mutant strain further comprises a genetic modification that deletes, disrupts or reduces the expression / production of a gene encoding at least one protein selected from the group consisting of MPG1 SFB3, SEB1, CRZ1, TSP2, SSB7 and GAS1. Therefore, certain related embodiments relate to a protein of interest produced by the mutant strain.
[0034] Other embodiments of the present disclosure relate to methods for constructing modified Ascomycota cells comprising an increased protein productivity phenotype, the method comprising (i) obtaining a parent cell comprising a wild-type lov gene, wherein the lov gene hybridizes under stringent hybridization conditions with a nucleic acid sequence encoding a LOV protein of SEQ ID NO:2, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 or SEQ ID NO:18, (ii) modifying the parent cell of step (i) to produce a modified cell comprising a gene encoding a LOV (variant) protein, wherein the LOV (variant) protein comprises a lysine (K) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:2, and (iii) isolating the modified cell of step (ii), wherein the modified cell comprises an increased protein productivity phenotype relative to the parent cell.
[0035] In other embodiments, the present disclosure relates to a method for constructing a modified Ascomycota cell comprising an increased protein productivity phenotype, the method comprising: (i) obtaining a parent Ascomycota cell and introducing a polynucleotide construct encoding a LOV variant protein into the cell, wherein the LOV variant protein comprises a lysine (K) residue at the amino acid sequence position corresponding to position 813 of SEQ ID NO:4, and (ii) isolating the modified cell of step (i), wherein the modified cell comprises an increased protein productivity phenotype relative to the parent cell.
[0036] Thus, as illustrated and described herein, various embodiments of the present disclosure are generally directed to variant strains of filamentous fungi comprising an enhanced protein productivity phenotype that are well suited for growth in submerged culture, such as for large-scale production of a protein of interest for commercial applications.
[0037] Brief description of biological sequence
[0038] SEQ ID NO: 1 is the nucleic acid sequence of the wild-type Trichoderma sp. lov gene encoding the (native) LOV protein of SEQ ID NO:2.
[0039] SEQ ID NO:2 is the amino acid sequence of the (native) LOV protein encoded by SEQ ID NO:1.
[0040] SEQ ID NO:3 is the nucleic acid sequence of a Trichoderma sp. mutant allele designated "lov(T813K)" encoding the (variant) T813K (substituted) LOV protein of SEQ ID NO:4.
[0041] SEQ ID NO:4 is the amino acid sequence of the (variant) T813K (substituted) LOV protein encoded by SEQ ID NO:3.
[0042] SEQ ID NO:5 is the amino acid sequence of the Trichoderma sp. MPG1 protein.
[0043] SEQ ID NO: 6 is the amino acid sequence of the Trichoderma sp. SEB1 protein.
[0044] SEQ ID NO: 7 is the amino acid sequence of the Trichoderma sp. SFB3 protein.
[0045] SEQ ID NO: 8 is the amino acid sequence of the Trichoderma sp. CRZ1 protein.
[0046] SEQ ID NO:9 is the amino acid sequence of the Trichoderma sp. GAS1 protein.
[0047] SEQ ID NO: 10 is the amino acid sequence of the Trichoderma sp. TPS2 protein.
[0048] SEQ ID NO: 11 is the amino acid sequence of an ortholog of the Aspergillus sp. LOV protein.
[0049] SEQ ID NO: 12 is the amino acid sequence of an ortholog of the Penicillium sp. LOV protein.
[0050] SEQ ID NO: 13 is the amino acid sequence of a Talaromyces species LOV protein ortholog.
[0051] SEQ ID NO: 14 is the amino acid sequence of a Fusarium sp. LOV protein ortholog.
[0052] SEQ ID NO: 15 is the amino acid sequence of an ortholog of the Myceliophthora sp. LOV protein.
[0053] SEQ ID NO: 16 is the amino acid sequence of a Neurospora sp. LOV protein ortholog.
[0054] SEQ ID NO: 17 is the amino acid sequence of a Candida sp. LOV protein ortholog.
[0055] SEQ ID NO: 18 comprises the C-terminal amino acid residue positions 500-894 of the Trichoderma sp. (native) LOV protein (SEQ ID NO: 2).
[0056] SEQ ID NO: 19 is the amino acid sequence of a variant Trichoderma histidine kinase (NIK1) comprising a methionine (M) to threonine (T) substitution at amino acid (residue) position 743 of SEQ ID NO: 19. The gene encoding the variant NIK1 histidine kinase of SEQ ID NO: 19 was named "nik1(M743T)".
[0057] SEQ ID NO:20 is the nucleic acid sequence of the wild-type Trichoderma reesei ssb7 gene encoding the native SSB7 protein of SEQ ID NO:21.
[0058] SEQ ID NO:21 is the amino acid sequence of the native Trichoderma reesei SSB7 protein encoded by SEQ ID NO:20.
[0059] SEQ ID NO:22 is the nucleic acid sequence of the allele ssb7(fs), which contains a G deletion (ΔG) in exon 2, resulting in a frameshift (fs) mutation, and contains a premature stop codon before the last intron of the ssb7 gene.
[0060] SEQ ID NO:23 is the amino acid sequence of the variant SSB7 protein encoded by the allele ssb7(fs) of SEQ ID NO:22.
[0061] SEQ ID NO:23 is the amino acid sequence of an ortholog of the Trichoderma harzianum LOV protein. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] Figure 1 The B7ms1 (parent) strain expressing glucoamylase is shown ( Figure 1 , gray data points / gray line) and mutant-derived (progeny) B7ms1-SF12 strains ( Figure 1 , black data points / black line). Therefore, the protein productivity of these strains expressing glucoamylase (GA) (containing viscosity-reducing mutations in the mpg1 and seb1 genes) in fermenters was evaluated. The legend shows the strain name of each strain type (see Table 1 for genotype), followed by the lov allele in the strain in parentheses. Figure 1 As shown, B7ms1-SF12 (progeny) strain ( Figure 1 , black line; i.e., strains containing the mutant lov(T813K) allele) relative to the B7ms1 (parental) strain ( Figure 1 , gray line; i.e., containing the wild-type lov gene) has an increased protein productivity phenotype. Figure 1As shown, when the lov(T813K) mutation was present, the protein yield from the supplied sugar was increased by 44%.
[0063] Figure 2 is a diagram illustrating the amino acid conservation of LOV protein. More specifically, Figure 2 is a graphical representation of the Geneious multiple sequence alignment of six hundred and ninety-one (691) Pezizomycotina homologs. Figure 2 At the bottom of the diagram is a box representing the amino acid sequence of the Trichoderma LOV protein, where the amino acid (residue) is presented in a black shaded box if it is conserved in greater than 99% of the aligned sequences (or gray otherwise). The LOV residue number (SEQ ID NO: 2) is presented above the sequence representation. Figure 2 The amino acid sequence gaps present in Trichoderma LOV or in the multiple sequence alignment sequence greater than 2% are presented in gray hatching. Annotations in the public GenBank sequence of LOV (XP_006967324.1) are shown as gray boxes below the sequence representation. As annotated in the GenBank entry for LOV, putative active site residues are shown as black boxes below the sequence representation. The substitution of threonine (T) 813 residue with lysine (K) in strain B7ms1-SF12 is annotated with a light gray box. The average hydrophobicity and isoelectric point ( P I) and presented in Figure 2 The amino acid identities in the alignment are plotted directly above the sequences. The lighter grey bars represent residues that are identical in at least 30% of the sequences in the alignment, and the darker bars represent residues that are identical in less than 30% of the sequences in the alignment.
[0064] Figure 3 A comparison of the total protein yield of the whole cellulase producing T4ms strain (grey line) and the mutant derived T4mls (black line) containing the engineered lov(T813K) allele in the fermentor on the fed sugar is presented. More specifically, Figure 3 The total protein yield of the supplied sugars for these strains under two fermentation conditions, low cell density (LCD, dotted line, circles) and high cell density (HCD, solid line, squares), is presented. The legend shows the fermentation conditions (LCD vs. HCD), followed by the strain name (genotypes see Table 1), and the presence of lov alleles is shown in brackets. Thus, Figure 3 As shown, under the two fermentation conditions of LCD (dashed line, circle) and HCD (solid line, square), the T4mls strain ( Figure 3 , black line; i.e., containing the mutant lov(T813K) allele) relative to the T4ms strain ( Figure 3 , gray line; i.e., containing the wild-type lov gene) all have a phenotype of increased protein productivity. Figure 3 As shown, when the lov(T813K) mutation was present, the protein yield from the fed sugar was increased by 42% (LCD) and 32% (HCD).
[0065] Figure 4 A comparison of the total protein yield of the fed sugar in the fermenter for the full cellulase production strains T4m (solid line, squares) and T4s (dashed line, circles) with wild-type lov alleles (grey lines) and their mutant derivatives T4ml+ (solid line, squares) and T4sl+ (dashed line, circles) containing the engineered lov(dis) alleles (black lines), respectively, is presented. The legend shows the strain name of each strain type (see Table 1 for genotypes), followed by the lov allele in the strain in parentheses. Figure 4 As shown, T4ml+ and T4sl+ (progeny) strains ( Figure 4 , black line; i.e., strains containing the mutant lov(dis) allele) relative to their T4m and T4s (parental) strains ( Figure 4 , grey line; i.e., containing the wild-type lov gene) does not have a protein productivity enhancement phenotype.
[0066] Figure 5 A comparison of the relative total protein titers of strains with the lov(T813K) allele, the lov(dis) allele, or the wild-type lov(+) allele and various marker insertion sites in shake flask fermentations is presented. More specifically, the total protein titers of the whole cellulase production strains were evaluated in shake flasks relative to the T4 strain and T4m strain operated in parallel. The strains with various marker insertion sites in fermentation were compared with the wild-type lov(+) allele ( Figure 5 , lightest grey bar), mutant lov(T813K) allele ( Figure 5 , medium grey bars) or the lov(dis) allele ( Figure 5 , darkest grey bar). Thus, in all marker insertion sites evaluated, total protein titers increased when the lov(T813K) allele was present. However, insertion of pyr4( Figure 5 , strain "41G") or the pyr2 marker (strains T4 and T4m) showed no significant improvement in relative titers.
[0067] Figure 6 The whole cellulase production T4mp strain ( Figure 6 , gray data points / gray line) and the lov(T813K) mutant T4mlp strain ( Figure 6, black data points / black line) of the total protein yield of the supplied sugar. Therefore, the protein productivity of these full cellulase expression strains in the fermentor was evaluated. The legend shows the strain name of each strain type (see Table 1 for genotype), followed by the lov allele in the strain in parentheses. Figure 6 As shown, the T4mlp strain ( Figure 6 , black line; i.e., strain containing the mutant lov(T813K) allele) relative to the T4mp (parental) strain ( Figure 6 , gray line; i.e., containing the wild-type lov gene) has an increased protein productivity phenotype. Figure 6 As shown, when the lov(T813K) mutation was present, the protein yield from the supplied sugar was increased by 28%.
[0068] FIG7 presents a Clustal W (1.83) multiple sequence alignment of the Trichoderma sp. (native) LOV protein (SEQ ID NO: 2) with seven (7) different Ascomycota LOV orthologs. For example, the eight (8) protein sequences used in the Clustal alignment are Figure 7A-7B As shown in (SEQ ID NO: 2 and SEQ ID NO: 11-17), and its Clustal alignment is as follows Figure 7C-7F More specifically, Figure 7C-7F As presented, the Trichoderma species (native) LOV protein (SEQ ID NO:2; labeled "2", residues shown in bold capital letters) is aligned with the following: an Aspergillus species LOV protein ortholog (SEQ ID NO: 11, labeled "11"), a Penicillium species LOV protein ortholog (SEQ ID NO: 12, labeled "12"), a Talaromyces species LOV protein ortholog (SEQ ID NO: 13, labeled "13"), a Fusarium species LOV protein ortholog (SEQ ID NO: 14, labeled "14"), a Myceliophthora species LOV protein ortholog (SEQ ID NO: 15, labeled "15"), a Neurospora species LOV protein ortholog (SEQ ID NO: 16, labeled "16"), and a Candida species LOV protein ortholog (SEQ ID NO: 17, labeled "17"). Figure 7C-7F As shown in the table (i.e., below the aligned amino acid residues), an asterisk "*" indicates a position with a single completely conserved residue, a colon ":" indicates conservation between groups of strong similar properties (i.e., scores > 0.5 in the Gonnet PAM 250 matrix), and a period "." indicates conservation between groups of weak similar properties (i.e., scores < 0.5 in the Gonnet PAM 250 matrix). The highly conserved threonine (T) amino acid is Figure 7F In bold and underlined T Residue indication.
[0069] Figure 8 presents an amino acid sequence alignment using the C-terminal residue positions 500-894 (SEQ ID NO: 18) of the (native) Trichoderma sp. LOV protein sequence (SEQ ID NO: 2) using BLAST protein alignment (NCBI; Blastp suite). Figure 8A-8G As presented, SEQ ID NO:18 comprises the C-terminal amino acid sequence of the Trichoderma sp. (native) LOV protein (i.e., comprising 394 amino acid residue positions corresponding to amino acid residue positions 500-894 of SEQ ID NO:2), wherein residue position 813 contains a highly conserved threonine (T) amino acid. 813 ) in bold and underlined T Therefore, the 394 residue C-terminal amino acid sequence (SEQ ID NO: 18) was compared with the orthologs of Ascomycota LOV proteins (e.g., SEQ ID NOs: 11-17; Figure 8A-8G ) comparison. Fig. 8A As shown, the Aspergillus species LOV protein ortholog (SEQ ID NO: 11) has about 50% amino acid sequence identity with SEQ ID NO: 18, wherein the highly conserved threonine ( T )Amino acids are bold and underlined ( Fig. 8A ), a Penicillium species LOV protein ortholog (SEQ ID NO: 12) has about 50% amino acid sequence identity with SEQ ID NO: 18, wherein the highly conserved threonine ( T )Amino acids are bold and underlined ( Figure 8B ), a Talaromyces species LOV protein ortholog (SEQ ID NO: 13) has about 60% amino acid sequence identity with SEQ ID NO: 18, wherein the highly conserved threonine ( T )Amino acids are bold and underlined ( Figure 8C ), a Fusarium species LOV protein ortholog (SEQ ID NO: 14) has about 88% amino acid sequence identity with SEQ ID NO: 18, wherein the highly conserved threonine ( T )Amino acids are bold and underlined ( Fig.8D), a Myceliophthora species LOV protein ortholog (SEQ ID NO: 15) has about 90% amino acid sequence identity with SEQ ID NO: 18, wherein the highly conserved threonine ( T )Amino acids are bold and underlined ( Fig. 8E ), a Neurospora species LOV protein ortholog (SEQ ID NO: 16) has about 90% amino acid sequence identity with SEQ ID NO: 18, wherein the highly conserved threonine ( T )Amino acids are bold and underlined ( Figure 8F ), and the Candida species LOV protein ortholog (SEQ ID NO: 17) has about 50% amino acid sequence identity with SEQ ID NO: 18, wherein the highly conserved threonine ( T )Amino acids are bold and underlined ( Figure 8G ). DETAILED DESCRIPTION
[0070] As set forth and described herein, the present disclosure addresses certain ongoing and unmet needs in the field of filamentous fungal protein production and methods thereof, including but not limited to the following genetic modification of filamentous fungi that produces a variant strain of filamentous fungi comprising a protein productivity-enhancing phenotype. More specifically, as presented, described and exemplified herein, such variant strains of filamentous fungi comprising a protein productivity-enhancing phenotype are well suited for growth in submerged culture, such as for large-scale production of a protein of interest for commercial applications.
[0071] I. Definitions
[0072] Before describing bacterial strain and method of the present invention in detail, the following terms are defined for clarity. Undefined terms should conform to the conventional meaning used in the relevant field. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention's compositions and methods belong.
[0073] Filamentous fungal cells for manipulation, construction and use as described herein are typically from the subdivision Pezizomycotina of the Ascomycota, particularly fungi with a vegetative hyphal state. Such organisms include filamentous fungal cells for the production of commercially important industrial and pharmaceutical proteins, including but not limited to Trichoderma species, Aspergillus species, Fusarium species, Penicillium species, Chrysosporium species, Cephalosporium species, Talaromyces species, Geosmithia species, Neurospora species, Myceliophthora species, and the like. For example, in certain embodiments, filamentous fungal cells and strains thereof include, but are not limited to, Trichoderma reesei (formerly classified as Trichoderma longibrachiatum and Hypocrea jecorina), Aspergillus niger, Aspergillus fumigatus, Aspergillus itaconicus, Aspergillus oryzae, Aspergillus nidulans, Aspergillus terreus, Aspergillus sojae, Aspergillus japonicus, Neurospora crassa, Penicillium funiculosum), Penicillium chrysogenum, Talaromyces (Geosmithia) emersonii, Fusarium venenatum, Myceliophthora thermophila, Chrysosporium lucknowense (C1), etc.
[0074] As used herein, terms and phrases such as "one or more filamentous fungal strains," "one or more fungal strains," "one or more filamentous fungal cells," "one or more filamentous fungal cells," "one or more fungal cells," etc. may be used interchangeably for ease of description and are not intended to limit the scope of the present disclosure.
[0075] In certain embodiments, filamentous fungal cells for manipulation, construction, and use as described herein are generally from the subdivision Pezizomycotina of the phylum Ascomycota, particularly fungi having a vegetative hyphal state and comprising a lov gene (or one or more lov gene homologs).
[0076] As used herein, phrases such as "parent cell," "parent fungal cell," "parent strain," "parent fungal strain," "parent strain of filamentous fungal cell," "reference strain," and the like are used interchangeably and refer to an "unmodified" parent filamentous fungal cell. For example, a "parent strain of a filamentous fungal cell" refers to any cell or strain of a filamentous fungus, wherein the genome of the "parent" cell is modified or modifiable (e.g., by introducing only one genetic modification of the parent cell) to produce a variant (progeny) strain of the filamentous fungal cell, such that the "parent" and "progeny" cells differ in only one genetic modification.
[0077] As used herein, phrases such as "variant cell", "daughter cell", "variant strain", "daughter strain", "variant or daughter fungal strain", "variant or daughter strain of a filamentous fungal cell", etc., are used interchangeably and refer to a variant strain of a filamentous fungal cell derived from (i.e., obtained or obtainable from) a parent (or reference) strain of a filamentous fungal cell, wherein the variant strain contains only one genetic modification that is not present in the parent strain, and thus, by comparison, the phenotypic differences between the "parent" and "variant" strains can be attributed to the one genetic modification. In other words, except for the single genetic modification that is "introduced" into the variant strain, the parent and variant strains are otherwise isogenic. Thus, in the present disclosure, parent and variant strains may be described as having certain characteristics, such as genetic modifications, expression phenotypes, morphological phenotypes, etc.; however, a skilled artisan will understand that, technically, it is the cell of the parent or variant strain that has such characteristics, and reference to a "strain" is made for convenience.
[0078] In certain embodiments, an unmodified (parental) cell may be referred to as a "control cell" or "reference cell," particularly when compared (compared) to a genetically modified (variant / progeny) cell derived therefrom.
[0079] As used herein, the terms "wild type" and "native" are used interchangeably and refer to a gene, protein, protein mixture or strain as found in nature.
[0080] As used herein, certain Trichoderma reesei strains / cells of the present disclosure have been named / abbreviated as described in Table 1 below.
[0081] Table 1
[0082] Trichoderma reesei strains and genetic modifications
[0083]
[0084]
[0085] As used herein, the reduced viscosity Trichoderma strain "B7ms1" is a strain expressing a glucoamylase, which is referred to as "Morph TrGA77B7Δmpg1Δseb1" in International PCT Publication No. WO 2012 / 145584, which is herein incorporated by reference in its entirety.
[0086] As used herein, genomic coordinates (e.g., 425393 on scaffold sequence 16) and protein identification numbers (PIDs, e.g., PID 50212) refer to version 2 of the T. reesei QM6a genome sequence assembly generated by the Department of Energy Joint Genome Institute (JGI) (The Genome Portal of the Department of Energy Joint Genome Institute, Grigoriev et al., Nucleic Acids Res 2012 Jan;40(Database Special):D26-32.doi:10.1093 / nar / gkr947). The sequences of the JGI assembled scaffold sequences have also been deposited in GenBank (The National Center for Biotechnology) under nucleotide accession numbers GL985056.1 to GL985132.1.
[0087] As used herein, a mutant (variant) Trichoderma strain designated "B7ms1-SF12" (derived from a B7ms1 parent strain) comprises an increased protein productivity phenotype (i.e., relative to the B7ms1 (parent) strain). More specifically, the mutation identified in the Trichoderma B7ms1-SF12 strain alters the coding sequence of a protein designated LOV (i.e., predicted protein PID 50212; SEQ ID NO: 2), wherein in the (mutant) B7ms1-SF12 strain, a highly conserved threonine (T) amino acid (T813) at residue position 813 of the (native) LOV protein (SEQ ID NO: 2) is substituted with lysine (T→K813) (i.e., T813K substitution, e.g., compare SEQ ID NO: 2 position 813 with SEQ ID NO: 4 position 813). For example, as described in the Examples section below, the lov mutant allele in strain B7ms1-SF12 contains a single nucleotide change from G (guanine) to T (thymine) at position 425393 on scaffold sequence 16, resulting in a "T813K" substitution in the encoded LOV (variant) protein (SEQ ID NO:4), which contains a lysine (K) at amino acid position 813 of SEQ ID NO:4 (as compared to the native LOV protein of SEQ ID NO:2, which contains a threonine (T) at amino acid position 813; SEQ ID NO:2).
[0088] As used herein, the Trichoderma strain designated "T4" is derived from Trichoderma strain RL-P37 by incorporation of the nik1 (M743T) mutation and chemical mutagenesis as described in International PCT Publication No. WO 2016 / 130523, which is incorporated herein by reference in its entirety.
[0089] As used herein, the allele designated "nik1(M743T)" comprises a mutant histidine kinase gene (nik1) encoding a variant histidine kinase (NIK1; SEQ ID NO:19) comprising a methionine (M) to threonine (T) substitution at amino acid (residue) position 743 of SEQ ID NO:19.
[0090] As used herein, the Trichoderma strain designated "T4_pyr2" is derived from Trichoderma strain T4 by mutation and loss of function of the pyr2 gene so that the pyr2 gene can be used as a transformation selectable marker.
[0091] As used herein, the Trichoderma strain named "T4m" is derived from strain T4, wherein strain T4m comprises a mpg1 gene mutation (Δmpg1) and a nik1 (M743T) gene. Thus, strain T4m comprises a wild-type lov allele (i.e., allele lov(+)) encoding a native lov protein (SEQ ID NO: 2).
[0092] As used herein, the Trichoderma strain designated "T4m_pyr2" is derived from strain T4m, wherein strain T4m_pyr2 comprises a mpg1 gene mutation (Δmpg1), a nik1 (M743T) gene, and a non-functional pyr2 gene.
[0093] As used herein, the Trichoderma strain designated "T4ml+" is derived from strain T4m_pyr2, wherein strain T4ml+ comprises a mutation in the mpg1 gene (Δmpg1) and the allele lov(dis).
[0094] As used herein, the Trichoderma strain designated "T4ml" is derived from strain T4ml+, wherein strain T4ml comprises nik1 (M743T), a mutation in the mpg1 gene (Δmpg1), an allele lov (T813K), and a non-functional pyr2 gene.
[0095] As used herein, the Trichoderma strain designated "T4mls" is derived from strain T4ml, wherein strain T4mls comprises nik1 (M743T), a double mutation in the mpg1 and seb1 genes (Δmpg1; Δseb1), and the allele lov (T813K).
[0096] As used herein, the Trichoderma strain designated "T4ms" is derived from strain T4m, wherein strain T4ms comprises nik1 (M743T) and a double mutation in the mpg1 and seb1 genes (Δmpg1; Δseb1).
[0097] As used herein, the Trichoderma strain designated "T4s" is derived from strain T4, wherein strain T4s comprises mutations in nik1 (M743T) and seb1 genes (Δseb1).
[0098] As used herein, the Trichoderma strain designated "T4s_pyr2" is derived from strain T4s, wherein strain T4s_pyr2 comprises nik1 (M743T), a seb1 gene mutation (Δseb1), and a non-functional pyr2 gene.
[0099] As used herein, the Trichoderma strain designated "T4sl+" is derived from strain T4s_pyr2, wherein strain T4sl+ comprises nik1 (M743T), a seb1 gene mutation (Δseb1), and the allele lov (dis).
[0100] As used herein, the Trichoderma strain designated "T4sl" is derived from strain T4sl+, wherein strain T4sl comprises nik1 (M743T), a seb1 gene mutation (Δseb1), allele lov (T813K), and a non-functional pyr2 gene.
[0101] As used herein, the Trichoderma strain designated "T41+" is derived from strain T4_pyr2, wherein strain T41+ comprises nik1(M743T) and allele lov(dis).
[0102] As used herein, the Trichoderma strain designated "41G" is mutagenesis derived from strain T4, wherein strain 41G comprises the nik1(M743T) and (wild type) lov(+) alleles.
[0103] As used herein, the Trichoderma strain designated "41G_pyr4" is derived from strain 41G, wherein strain 41G_pyr4 comprises nik1(M743T), the (wild type) lov(+) allele and has a deletion of the pyr4 gene.
[0104] As used herein, the Trichoderma strain designated "41G1+" is derived from strain 41G_pyr4, wherein strain 41G1+ comprises nik1(M743T) and allele lov(dis).
[0105] As used herein, the Trichoderma strain designated "T4mc" is derived from strain T4m_pyr2, wherein strain T4mc comprises nik1(M743T), Δmpg1, a pyr2+ insertion at site C, and a wild-type lov(+) allele.
[0106] As used herein, the Trichoderma strain designated "T4mlc" is derived from strain T4ml, wherein strain T4mlc comprises nik1(M743T), Δmpg1, a pyr2+ insertion at site C, and allele lov(T813K).
[0107] As used herein, the Trichoderma strain designated "T4md" is derived from strain T4m_pyr2, wherein strain T4md comprises nik1(M743T), Δmpg1, a pyr2+ insertion at site B, and a wild-type lov(+) allele.
[0108] As used herein, the Trichoderma strain designated "T4mld" is derived from strain T4ml, wherein strain T4mld comprises nik1(M743T), Δmpg1, a pyr2+ insertion at site B, and allele lov(T813K).
[0109] As used herein, the Trichoderma strain designated "T4mp" is derived from strain T4m_pyr2, wherein strain T4mp comprises nik1(M743T), Δmpg1, a pyr2+ insertion at site A, and a wild-type lov(+) allele.
[0110] As used herein, the Trichoderma strain designated "T4mlp" is derived from strain T4ml, wherein strain T4mlp comprises nik1(M743T), Δmpg1, a pyr2+ insertion at site A, and allele lov(T813K).
[0111] As used herein, the Trichoderma strain designated "T4sp" is derived from strain T4s_pyr2, wherein strain T4sp comprises nik1(M743T), Δseb1, a pyr2+ insertion at site A, and a wild-type lov(+) allele.
[0112] As used herein, the Trichoderma strain designated "T4slp" is derived from strain T4sl, wherein strain T4slp comprises nik1(M743T), Δseb1, a pyr2+ insertion at site A, and allele lov(T813K).
[0113] As used herein, a "glucoamylase (GA) construct" or "GA construct" encodes a glucoamylase described in PCT Publication No. WO 2012 / 145584, specifically incorporated herein by reference in its entirety.
[0114] As used herein, "allele lov(+)" comprises a wild-type lov DNA sequence encoding a native LOV protein (eg, SEQ ID NO: 2).
[0115] As used herein, "allele lov(T813K)" comprises a mutated (lov) DNA sequence (identified in strain B7ms1-SF12 as described above) encoding a variant LOV protein (SEQ ID NO: 4 above) comprising a "T813K" substitution.
[0116] As used herein, "allele lov(dis)" comprises a disruption of the lov gene, wherein the selectable marker pyr2 or pyr4 is integrated into the lov coding sequence, as further described in Example 3 below.
[0117] As used herein, "full cellulase strain" refers to a Trichoderma strain in which the natural secretome has not been altered by genetically engineering the major cellulase genes.
[0118] As used herein, "endogenous (or native) filamentous fungal genes" encoding a protein of interest include, but are not limited to, endogenous (filamentous fungal) genes encoding glycoside hydrolase (GH) family enzymes (such as, for example, EC No. 3.2.1.1-3.2.1.206), endogenous genes encoding proteases, esterases, lipases, etc., as known and understood by those skilled in the art.
[0119] Thus, as generally described herein, substitution of a threonine (T) amino acid with a lysine (K) at an amino acid (residue) position equivalent to position 813 of a (variant) LOV protein of SEQ ID NO: 4 (T→K substitution) has been identified herein as being responsible for the observed protein productivity (increased) phenotype. For example, when fermented / cultured under the same conditions, strains T comprising the encoding (mutant) B7ms1-SF12 disclosed herein 813 → 813 Filamentous fungal cells containing an introduced allele of a K substitution (e.g., allele lov(T813K)) exhibit an increased protein productivity phenotype relative to isogenic cells lacking this mutation (i.e., comprising a wild-type lov gene encoding a native LOV protein, i.e., allele lov(+)). More particularly, as presented in the Examples section below, the filamentous fungal cells of the present disclosure (comprising such an increased protein productivity phenotype) are particularly suitable for growth in (aerobic) submerged culture (e.g., such as for large-scale production of a protein of interest for commercial applications).
[0120] As used herein, the "positions" of amino acid residues in a "given amino acid sequence" are numbered using the amino acid residue numbers (positions) of the native Trichoderma sp. LOV protein of SEQ ID NO: 2. For example, for the phrases "comprising a threonine (T) residue at the sequence position corresponding to position 813 of SEQ ID NO: 2" and "comprising a lysine (K) residue at the sequence position corresponding to position 813 of SEQ ID NO: 2," the amino acid sequence of the native (Trichoderma sp.) LOV protein (SEQ ID NO: 2) is used as the reference (parent) protein sequence.
[0121] For example, Figure 7C-7FAs shown in, the given amino acid sequence described herein can be aligned with the natural Trichoderma species LOV protein amino acid sequence (SEQ ID NO: 2) using the alignment algorithm described herein (and / or an alignment algorithm known in the art), and the amino acid residues in the given amino acid sequence that are aligned (preferably optimally aligned) with the amino acid residues in the natural sequence can be conveniently numbered by reference to the corresponding amino acid residues in the LOV sequence. Thus, Figure 7 presents a multiple sequence alignment of the native Trichoderma species LOV protein (SEQ ID NO:2) labeled as sequence "2" with orthologs of the LOV protein from various (Ascomycota) filamentous fungi, such as Aspergillus species (SEQ ID NO:12) labeled as sequence "12", Penicillium species (SEQ ID NO:13) labeled as sequence "13", Talaromyces species (SEQ ID NO:14) labeled as sequence "14", Fusarium species (SEQ ID NO:15) labeled as sequence "15", Myceliophthora species (SEQ ID NO:16) labeled as sequence "16", Neurospora species (SEQ ID NO:17) labeled as sequence "17", and Candida species (SEQ ID NO:18) labeled as sequence "18".
[0122] Similarly, to establish sequence homology or sequence identity with the primary (1°) sequence of the Trichoderma sp. LOV protein (SEQ ID NO:2), one skilled in the art can readily compare the primary sequence of SEQ ID NO:2 with one or more candidate LOV protein (ortholog) sequences using sequence alignment algorithms, software, and methods known to those skilled in the art. Thus, after aligning the conserved residues, allowing for necessary insertions and deletions to maintain the alignment (i.e., avoiding elimination of conserved residues by arbitrary deletions and insertions), residues equivalent to specific amino acids in the primary sequence of the Ascomycota LOV protein are defined. The alignment of conserved residues should preferably retain 100% of such residues. However, alignment of greater than 98%, 95%, 90%, 85%, 80%, 75%, 70%, 50%, or at least 45% of the conserved residues is also sufficient to define equivalent residues.
[0123] Thus, as used herein, at the amino acid (residue) position corresponding to (or equivalent to) position 813 of SEQ ID NO: 2, a lysine (K) amino acid is substituted for a threonine (T) amino acid (T 813 → 813 K substitution) includes any T at the amino acid (residue) position corresponding to position 813 of SEQ ID NO: 2 in any Ascomycota filamentous fungal cell. 813 → 813 K replaced.
[0124] As used herein, the term "gene" is synonymous with the term "allele" and refers to a nucleic acid that encodes and directs the expression of a protein or RNA. Vegetative forms of filamentous fungi are typically haploid, so a single copy of a given gene (i.e., a single allele) is sufficient to confer a specific phenotype.
[0125] As used herein, the terms "polypeptide" and "protein" (and / or their respective plural forms) are used interchangeably to refer to polymers of any length comprising amino acid residues linked by peptide bonds. Conventional one-letter or three-letter codes for amino acid residues are used herein. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. These terms also include amino acid polymers modified naturally or by intervention; for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as coupling with a labeling component. Also included within the definition are, for example, polypeptides containing one or more amino acid analogs (including, for example, non-natural amino acids, etc.) and other modifications known in the art.
[0126] As used herein, the term "derivative polypeptide / protein" refers to a protein derived or derivatable by adding one or more amino acids to one or both of the N-terminus and the C-terminus, replacing one or more amino acids at one or more different sites in the amino acid sequence, deleting one or more amino acids at one or both ends of the protein or at one or more sites in the amino acid sequence, and / or inserting one or more amino acids at one or more sites in the amino acid sequence. The preparation of protein derivatives can be achieved by modifying the DNA sequence encoding the native protein, transforming the DNA sequence into a suitable host, and expressing the modified DNA sequence to form a derivative protein.
[0127] Related (and derived) proteins include "variant proteins". Variant proteins are different from reference / parent proteins (e.g., wild-type proteins) by substitution, deletion and / or insertion at a small number of amino acid residues. The number of different amino acid residues between variant and parent protein can be one or more, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50 or more amino acid residues. Variant proteins can have at least about 50%, at least about 60%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or even at least about 99%, or more amino acid sequence identity with reference proteins. Variant proteins can also be different from reference proteins in terms of selected motifs, domains, epitopes, conserved regions, etc.
[0128] As used herein, the term "similar sequence" refers to a sequence in a protein that provides a function, tertiary structure and / or conserved residues similar to that of a target protein (i.e., typically the original protein of the target). For example, in an epitope region containing an α-helix or β-folded structure, the replacement amino acid in the similar sequence preferably maintains the same specific structure. The term also refers to a nucleotide sequence and an amino acid sequence. In some embodiments, similar sequences are developed so that the replacement of amino acids produces variant enzymes that display similar or improved functions. In some embodiments, the tertiary structure and / or conserved residues of amino acids in the target protein are located at or near the target segment or fragment. Therefore, when the target segment or fragment contains, for example, an α-helix or β-folded structure, the replacement amino acid preferably maintains the specific structure.
[0129] As used herein, the term "homologous protein" refers to a protein that has similar activity and / or structure to a reference protein. This is not intended to mean that homologs are necessarily evolutionarily related. Therefore, it is intended to mean that the term encompasses one or more proteins that are identical, similar, or corresponding (i.e., in terms of structure and function) obtained from different organisms. In some embodiments, it is desirable to identify homologs that have similar quaternary, tertiary, and / or primary structures to a reference protein.
[0130] The degree of homology between sequences can be determined using any suitable method known in the art (see, e.g., Smith and Waterman, 1981; Needleman and Wunsch, 1970; Pearson and Lipman, 1988; programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, WI); and Devereux et al., 1984).
[0131] For example, PILEUP is a useful program for determining the level of sequence homology. PILEUP uses progressive, pairwise comparisons to create a multiple sequence alignment from a group of related sequences. It can also draw a tree showing the clustering relationship used to create the comparison. PILEUP uses a simplification of the progressive comparison method of Feng and Doolittle (1987). The method is similar to the method described in Higgins and Sharp (1989). Useful PILEUP parameters include a default gap weight of 3.00, a default gap length weight of 0.10, and weighted terminal gaps. Another example of a useful algorithm is the BLAST algorithm described by Altschul et al., 1990 and Karlin et al., 1993. A particularly useful BLAST program is the WU-BLAST-2 program (see, e.g., Altschul et al., 1996). Parameters "W", "T" and "X" determine the sensitivity and speed of the comparison. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see, eg, Henikoff and Henikoff, 1989), alignments (B) 50, expectation (E) 10, M' 5, N' -4, and a comparison of both strands.
[0132] As used herein, the phrases "substantially similar" and "substantially identical" in the context of at least two nucleic acids or polypeptides typically mean that the polynucleotides or polypeptides comprise sequences having at least about 70% identity, at least about 75% identity, at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, or even at least about 99% identity, or higher identity compared to a reference (i.e., wild-type) sequence. Sequence identity can be determined using known programs such as BLAST, ALIGN, and CLUSTAL using standard parameters. (See, e.g., Altschul et al., 1990; Henikoff et al., 1989; Karlin et al., 1993; and Higgins et al., 1988). Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information. In addition, FASTA can be used to search databases (Pearson et al., 1988). An indication that two polypeptides are substantially identical is that the first polypeptide has immunological cross-reactivity with the second polypeptide. Typically, the difference is that the polypeptide substituted with conservative amino acids has immunological cross-reactivity. Therefore, the polypeptide is substantially identical to the second polypeptide, for example, wherein the two peptides differ only in conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions (e.g., within the range of medium to high stringency).
[0133] As used herein, "nucleic acid" refers to nucleotide or polynucleotide sequences and fragments or portions thereof, as well as DNA, cDNA and RNA of genomic or synthetic origin, which may be double-stranded or single-stranded, whether representing the sense or antisense strand.
[0134] As used herein, the term "expression" refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid molecules of the present disclosure. Expression can also refer to the translation of mRNA into polypeptides. Therefore, the term "expression" includes any steps involved in the production of polypeptides, including but not limited to transcription, post-transcriptional modification, translation, post-translational modification, secretion, etc.
[0135] As used herein, the combined terms "expression / production", as used in phrases such as "a variant strain of a filamentous fungal cell expresses / produces an 'increased' amount of a protein of interest (POI)" (i.e., relative to the parental cell), are intended to include any steps involved in expressing and producing a protein in such variant filamentous fungal strains of the present disclosure.
[0136] In certain embodiments, a gene, polynucleotide or nucleic acid sequence encoding a LOV protein comprising "sequence homology" refers to a DNA or RNA (nucleic acid) sequence that has minimal sequence differences from a corresponding nucleic acid sequence (when compared to said sequence) and retains substantially the same biological function as the corresponding nucleic acid sequence (when compared to said sequence). For example, in certain embodiments, a nucleic acid sequence having considerable sequence homology to a gene, polynucleotide or nucleic acid encoding a LOV protein is assessed by identifying the encoded gene product (LOV protein) as described herein.
[0137] In certain other embodiments, nucleic acid hybridization methods are used to determine / identify genes, polynucleotides or nucleic acid sequences that have sequence homology with genes, polynucleotides or nucleic acids encoding LOV proteins. For example, in certain embodiments, DNA / RNA sequences that have substantial sequence homology with genes encoding LOV proteins (e.g., SEQ ID NO: 2) are identified by the ability of such DNA / RNA sequences to hybridize with a designated nucleic acid sequence of the present disclosure under stringent conditions.
[0138] As used herein, "hybridization under stringent conditions" is intended to describe conditions for hybridization and washing, under which nucleotide sequences that are significantly identical or homologous to each other remain hybridized to each other. Such stringent conditions are well known to those skilled in the art (see, e.g., Ausubel et al., 1995; Sambrook et al., 1989). For example, in certain embodiments, non-limiting examples of stringent hybridization conditions include hybridization in 4X sodium chloride / sodium citrate (SSC) at about 65°C-70°C (or hybridization in 4×SSC plus 50% formamide at about 42°C-50°C), followed by washing with 1×SSC at about 65°C-70°C one or more times. Similarly, non-limiting examples of highly stringent hybridization conditions include hybridization in 1×SSC at about 65°C-70°C (or hybridization in 4×SSC plus 50% formamide at about 42°C-50°C), followed by washing with 0.3×SSC at about 65°C-70°C one or more times. Thus, highly stringent hybridization conditions include hybridization in 4×SSC at about 50°C-60°C (or alternatively, hybridization in 6×SSC plus 50% formamide at about 40°C-45°C), followed by one or more washes with 2×SSC at about 50°C-60°C. The present disclosure is also intended to encompass ranges intermediate to the above values, for example, at 65°C-70°C or at 42°C-50°C. In certain embodiments, SSPE (1×SSPE is 0.15M NaCl, 10mM NaH2PO4 and 1.25mM EDTA, pH 7.4) may be used in place of SSC (1×SSPE is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; after hybridization is complete, washes are performed for 15 minutes each. The hybridization temperature for hybrids expected to be less than 50 base pairs in length should be higher than the melting temperature (T m ) 5℃-10℃ lower, where T m Determined according to the following equation. For hybrids less than 18 base pairs in length, T m (°C) = 2(A + T bases) + 4(G + C bases). For hybrids between 18 and 49 base pairs in length, T m(°C) = 81.5 + 16.6 (log10 [Na +]) + 0.41 (% G + C) - (600 / N), where N is the number of bases in the hybrid, and [Na +] is the concentration of sodium ions in the hybridization buffer ([Na +] = 0.165 M for 1 × SSC). The skilled artisan will also recognize that other reagents may be added to the hybridization and / or wash buffer to reduce non-specific hybridization of nucleic acid molecules to membranes such as nitrocellulose or nylon membranes, including but not limited to blocking agents (e.g., BSA or salmon or herring sperm carrier DNA), detergents (e.g., SDS), chelating agents (e.g., EDTA), Ficoll, PVP, etc. In particular, when using a nylon membrane, another non-limiting example of stringent hybridization conditions is hybridization in 0.25-0.5 M NaH2PO4, 7% SDS at about 65°C, followed by one or more washes in 0.02 M NaH2PO4, 1% SDS at 65°C, or alternatively in 0.2X SSC, 1% SDS (see, e.g., Church and Gilbert, 1984).
[0139] Therefore, as generally described above, certain embodiments of the present disclosure relate to variant strains of filamentous fungal cells, the variant strains comprising genetic modifications of genes encoding LOV proteins. As used herein, the terms "modification" and "genetic modification" can be used interchangeably and include, but are not limited to: (a) introduction, substitution or removal of one or more nucleotides in a gene, or introduction, substitution or removal of one or more nucleotides in a regulatory element required for gene transcription or translation, (b) gene disruption, (c) gene transformation, (d) gene deletion, (e) downregulation of a gene (e.g., antisense RNA, siRNA, miRNA, etc.), (f) specific mutagenesis of any one or more genes disclosed herein (including but not limited to CRISPR / Cas9-based mutagenesis) and / or (g) random mutagenesis.
[0140] As used herein, variant strains of filamentous fungi comprising genetic modifications include, but are not limited to, genetic modifications of genes encoding LOV proteins disclosed herein. Therefore, various molecular biological methods are well known to those skilled in the art and can be used to generate / construct such variant strains of filamentous fungal cells, as further described below.
[0141] As used herein, "introduction, substitution or removal of one or more nucleotides in a gene encoding a protein", such genetic modification includes gene coding sequences (ie, exons) and non-coding intervening (intron) sequences.
[0142] As used herein, "disruption of a gene", "gene disruption", "inactivation of a gene" and "gene inactivation" are used interchangeably and broadly refer to any genetic modification that substantially disrupts / inactivates a target gene. Exemplary methods of gene disruption include, but are not limited to, complete or partial deletion of any portion of a gene (including a polypeptide coding sequence (CDS), a promoter, an enhancer or another regulatory element) or mutagenesis thereof, wherein mutagenesis encompasses substitutions, insertions, deletions, inversions and any combination and variation thereof, which disrupts / inactivates one or more target genes and substantially reduces or prevents the expression / production of a functional gene product. In certain embodiments of the present disclosure, such gene disruption prevents host cells from expressing / producing the encoded lov gene product.
[0143] In certain embodiments, the gene, polynucleotide or nucleic acid sequence encoding the LOV protein is genetically modified using established gene editing technologies, such as CRISPR / Cas9 gene editing, zinc finger nuclease (ZFN) gene editing, transcription activator-like effector nuclease editing (TALEN), homing (large) nuclease editing, etc.
[0144] In other embodiments, variant strains of filamentous fungi are constructed (ie, genetically modified) through the process of genetic transformation (eg, see Iglesias and Trautner, 1983).
[0145] In other embodiments, the target protein (e.g., endogenous POI or heterologous POI) expressed / produced by the Ascomycetes cells of the present disclosure is detected, identified, measured, determined, etc. by the following methods: protein quantification method, gene transcription method, mRNA translation method, etc., including but not limited to protein migration / mobility (SDS-PAGE), mass spectrometry, HPLC, size exclusion, ultracentrifugation sedimentation velocity analysis, transcriptomics, proteomics, fluorescent tags, epitope tags, fluorescent protein (GFP, RFP, etc.) chimeras / hybrids, etc.
[0146] As used herein, functionally and / or structurally similar proteins are considered "related proteins". Such related proteins may be derived from organisms of different genera and / or species, or even organisms of different classes (e.g., bacteria and fungi). Related proteins also encompass homologs and / or orthologs determined by primary sequence analysis, by secondary or tertiary structure analysis, or by immunological cross-reactivity.
[0147] As used herein, the term "promoter" refers to a nucleic acid sequence that can control the expression of a coding sequence or functional RNA. Typically, the coding sequence is located 3' (downstream) of the promoter sequence. The promoter can be derived from a natural gene in its entirety, or be composed of different elements from different promoters found in nature, or even comprise a synthetic nucleic acid segment. It will be appreciated by those skilled in the art that different promoters can guide gene expression in different cell types, or at different developmental stages, or in response to different environmental conditions or physiological conditions. The promoter that causes gene expression in most cell types is usually referred to as a "constitutive promoter" most of the time. It is further recognized that, since the exact boundaries of the regulatory sequence cannot be fully determined in most cases, DNA fragments of different lengths can have the same promoter activity.
[0148] As used herein, the term "effectively connected" refers to the association of nucleic acid sequences on a single nucleic acid fragment, so that the function of one nucleic acid fragment is affected by another. For example, when the expression of the coding sequence can be achieved (i.e., the coding sequence is under the transcriptional control of the promoter), the promoter is effectively connected to the coding sequence (e.g., ORF). The coding sequence can be effectively connected to the regulatory sequence in the sense or antisense direction. When a nucleic acid is placed in a functional relationship with another nucleic acid sequence, the nucleic acid is "effectively connected" to another nucleic acid sequence. For example, if the DNA encoding the secretory leader (i.e., signal peptide) is expressed as a preprotein participating in the secretion of a polypeptide, the DNA encoding the secretory leader is effectively connected to the DNA of the polypeptide; if the promoter or enhancer affects the transcription of the coding sequence, the promoter or enhancer is effectively connected to the sequence; or if the ribosome binding site is positioned to promote translation, the ribosome binding site is effectively connected to the coding sequence. Generally, "effectively connected" means that the DNA sequence being connected is continuous, and in the case of a secretory leader, it is continuous and in the reading phase. However, enhancers do not necessarily have to be continuous. Connection is achieved by connecting at a convenient restriction site. If such sites do not exist, these synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
[0149] As defined herein, "suitable regulatory sequences" refer to nucleotide sequences that are located upstream (5' non-coding sequences), internal or downstream (3' non-coding sequences) of a coding sequence and that affect transcription, RNA processing or stability or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, RNA processing sites, effector binding sites, and stem-loop structures.
[0150] As defined herein, the term "introduced", as used in phrases such as "introducing into a fungal cell" at least one polynucleotide open reading frame (ORF) or its gene or its vector, includes methods known in the art for introducing a polynucleotide into a cell, including but not limited to protoplast fusion, natural or artificial transformation (e.g., calcium chloride, electroporation), transduction, transfection, and the like.
[0151] As used herein, "transformed" or "transformation" refers to a cell that has been transformed using recombinant DNA techniques. Transformation typically occurs by inserting one or more nucleotide sequences (e.g., polynucleotides, ORFs, or genes) into a cell. The inserted nucleotide sequence may be a heterologous nucleotide sequence (i.e., a sequence that is not naturally present in the cell to be transformed).
[0152] As used herein, "conversion" refers to the introduction of exogenous DNA into a host cell so that the DNA remains as a chromosome integrant or a self-replicating extrachromosomal vector. As used herein, "conversion DNA", "conversion sequence" and "DNA construct" refer to the DNA for introducing a sequence into a host cell. DNA can be produced in vitro by PCR or any other suitable technology. In certain embodiments, the conversion DNA comprises an input sequence, and in other embodiments, it also comprises an input sequence flanking a homology box. In another embodiment, the conversion DNA comprises other non-homologous sequences (i.e., stuffing sequence or flank) added to the end. The end can be closed so that the conversion DNA forms a closed loop, such as, inserting into a vector.
[0153] As used herein, "input sequence" refers to a DNA sequence introduced into the fungal cell chromosome. In certain embodiments, the input sequence is a part of a DNA construct. In other embodiments, the input sequence encodes one or more target proteins. In certain embodiments, the input sequence comprises a sequence that may or may not be present in the genome of the cell to be transformed (that is, it may be a homologous or heterologous sequence). In certain embodiments, the input sequence encodes one or more target proteins, genes, and / or mutations or modified genes. In alternative embodiments, the input sequence encodes functional wild-type genes or operons, functional mutant genes or operons or non-functional genes or operons. In certain embodiments, the input sequence is a non-functional sequence inserted into a gene to destroy gene function. In another embodiment, the input sequence includes a selective marker. In a further embodiment, the input sequence includes two homology boxes.
[0154] As used herein, "homology box" refers to a nucleic acid sequence homologous to a sequence in a fungal cell chromosome. More specifically, according to the present invention, a homology box is an upstream or downstream region having a sequence identity between about 80% and 100%, a sequence identity between about 90% and 100%, or a sequence identity between about 95% and 100% with a direct flanking coding region of a gene or a part of a gene that is deleted, destroyed, inactivated, downregulated, etc. These sequences guide the integration position of the DNA construct in the fungal cell chromosome, and guide which part of the fungal cell chromosome is replaced by the input sequence. Although it is not intended to limit the present disclosure, the homology box may include about 1 base pair (bp) to 200 kilobases (kb). Preferably, the homology box includes between about 1 bp and 10.0 kb; between 1 bp and 5.0 kb; between 1 bp and 2.5 kb; between 1 bp and 1.0 kb, and between 0.25 kb and 2.5 kb. Homology boxes can also include about 10.0 kb, 5.0 kb, 2.5 kb, 2.0 kb, 1.5 kb, 1.0 kb, 0.5 kb, 0.25 kb, and 0.1 kb. In some embodiments, the 5' and 3' ends of the selectable marker are flanked by a homology box, wherein the homology box comprises a nucleic acid sequence that is immediately flanking the coding region of the gene.
[0155] As used herein, the term "nucleotide sequence encoding a selectable marker" refers to a nucleotide sequence that is capable of being expressed in a host cell and wherein expression of the selectable marker confers upon the cells containing the expressed gene the ability to grow in the absence of the corresponding selective agent or in the absence of essential nutrients.
[0156] As used herein, the terms "selectable marker" and "selective marker" refer to a nucleic acid (e.g., a gene) that can be expressed in a host cell that allows easy selection of those hosts containing the vector. Examples of such selectable markers include, but are not limited to, antimicrobial agents. Thus, the term "selectable marker" refers to a gene that provides an indication that the host cell has taken up the input DNA of interest or that some other reaction has occurred. Typically, a selectable marker is a gene that confers antimicrobial resistance or a metabolic advantage to the host cell to allow cells containing exogenous DNA to be distinguished from cells that have not received any exogenous sequences during transformation.
[0157] As defined herein, a host cell "genome", a fungal cell "genome" or a filamentous fungal cell "genome" includes chromosomal genes and extrachromosomal genes.
[0158] As used herein, the terms "plasmid", "vector" and "cassette" refer to an extrachromosomal element that usually carries genes that are typically not part of the central metabolism of the cell and is usually in the form of a circular double-stranded DNA molecule. Such elements can be linear or circular self-replicating sequences of single-stranded or double-stranded DNA or RNA derived from any source, genome integration sequences, phages, or nucleotide sequences in which many nucleotide sequences have been linked or recombined into a single structure that is capable of introducing a promoter fragment and DNA sequence for a selected gene product, along with appropriate 3' untranslated sequences, into a cell.
[0159] As used herein, the term "vector" refers to any nucleic acid that can replicate (propagate) in a cell and can carry a new gene or DNA fragment (e.g., an "input sequence") into a cell. Thus, the term refers to a nucleic acid construct designed to be transferred between different host cells. Vectors include viruses, phages, proviruses, plasmids, phagemids, transposons, and artificial chromosomes such as YACs (yeast artificial chromosomes), BACs (bacterial artificial chromosomes), PLACs (plant artificial chromosomes), etc., which are "episomes" (i.e., autonomously replicating) or can be integrated into the chromosome of a host cell.
[0160] As used herein, "transformation cassette" refers to a specific vector that contains a gene (or its ORF), and has elements other than the gene that facilitate transformation of a specific host cell.
[0161] "Expression vector" refers to a vector that has the ability to incorporate and express heterologous DNA in a cell. Many prokaryotic and eukaryotic expression vectors are commercially available and are well known to those skilled in the art. The selection of an appropriate expression vector is within the knowledge of those skilled in the art.
[0162] As used herein, the terms "expression cassette" and "expression vector" refer to a nucleic acid construct (i.e., these are vectors or vector elements, as described above) that is recombinantly or synthetically produced with a series of specific nucleic acid elements that allow a specific nucleic acid to be transcribed in a target cell. The recombinant expression cassette can be integrated into a plasmid, a chromosome, a mitochondrial DNA, a plastid DNA, a virus, or a nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes, in addition to other sequences, a nucleic acid sequence to be transcribed and a promoter. In some embodiments, the DNA construct also includes a series of specific nucleic acid elements that allow transcription of a specific nucleic acid in a target cell. In certain embodiments, the DNA construct of the present disclosure comprises a selective marker as defined herein and an inactivated chromosome or gene or DNA segment.
[0163] As used herein, "targeting vector" is a vector comprising a polynucleotide sequence homologous to a region in the chromosome of a host cell transformed with the targeting vector and capable of driving homologous recombination in the region. For example, a targeting vector can be used to introduce genetic modification into a host cell chromosome by homologous recombination. In certain embodiments, the targeting vector comprises other non-homologous sequences, such as other non-homologous sequences (i.e., stuffing sequences or flanking sequences) added to the ends. The ends can be closed so that the targeting vector forms a closed loop, such as, for example, inserted into a vector.
[0164] As used herein, variant cells (or strains) comprising a "protein productivity improvement phenotype" include, but are not limited to, variant cells (or strains) comprising an improved / increased volumetric productivity, variant cells (or strains) comprising an improved / increased carbon conversion efficiency, variant cells (or strains) having an improved / increased protein yield, variant cells (or strains) having an improved / increased specific protein productivity, etc. For example, in certain embodiments, a variant cell or strain comprising an improved protein productivity phenotype expresses / produces at least 0.1% or more of total protein (g) per gram of fed sugar (relative to the parent strain), wherein the fed sugar can be expressed as the mass of sugar added to the fermentor during the production phase (i.e., after the start of feeding) .
[0165] As defined herein, the phrases "enhanced protein productivity phenotype" and "increased protein productivity phenotype" are used interchangeably.
[0166] As used herein, when describing the "protein productivity improvement / increased phenotype" of an unmodified (parent) cell relative to a modified (variant / progeny) cell, it is understood that the "parent" and "variant" cells are grown / cultured / fermented under the same conditions (e.g., the same conditions such as culture medium, temperature, pH, etc.). Similarly, when describing the "expression / production" of a protein of interest (POI) in an unmodified (parent) cell relative to the "expression / production" of the same POI in a modified (variant / progeny) cell, it is understood that the "parent" and "variant" cells are grown / cultured / fermented under substantially the same conditions (e.g., the same conditions such as culture medium, temperature, pH, etc.).
[0167] As used herein, "aerobic fermentation" refers to growth in the presence of oxygen.
[0168] As used herein, the terms "broth", "cell broth", "fermentation broth" and / or "culture broth" are used interchangeably and refer generally to (i) fermentation (culture) medium and (ii) cells in liquid (submerged) culture.
[0169] As used herein, the term "cell mass" refers to the cellular components (including intact and lysed cells) present in liquid (submerged) culture. Cell mass can be expressed as dry cell weight (DCW) or wet cell weight (WCW).
[0170] As used herein, a "viscosity reduction" strain of a filamentous fungal cell refers to a modified (progeny) strain that produces a cell broth having a reduced viscosity (i.e., reduced resistance to shear stress or tensile stress) compared to an equivalent cell broth produced by a parent strain. For example, an equivalent cell broth typically has a comparable cell mass. Methods for constructing filamentous fungal strains with reduced viscosity and methods for comparing their viscosities are described in detail in International PCT Publication Nos. WO 2012 / 027580, WO 2012 / 145596, WO 2012 / 145596, and WO 2012 / 145592, and International PCT Application Serial No. PCT / US 2019 / 27590 (each of which is specifically incorporated herein by reference in its entirety).
[0171] Thus, in certain embodiments, a variant strain of the present disclosure (e.g., a variant strain comprising a genetic modification encoding the allele lov(T813K)) comprises an improved / increased protein productivity phenotype, wherein the variant strain also comprises a genetic modification of a gene encoding MPG1, SFB3, SEB1, CRZ1, GAS1, TPS2 and / or SSB7 protein.
[0172] As used herein, the Trichoderma sp. "MPG1 protein" comprises the amino acid sequence of SEQ ID NO: 5 (as described in International PCT Publication No. WO 2012 / 145584, which is herein incorporated by reference in its entirety).
[0173] As used herein, the Trichoderma sp. "SEB1 protein" comprises the amino acid sequence of SEQ ID NO: 6 (as described in International PCT Publication No. WO 2012 / 145595, which is herein incorporated by reference in its entirety).
[0174] As used herein, the Trichoderma sp. "SFB3 protein" comprises the amino acid sequence of SEQ ID NO: 7 (as described in International PCT Publication No. WO 2012 / 027580, which is herein incorporated by reference in its entirety).
[0175] As used herein, the Trichoderma sp. "CRZ1 protein" comprises the amino acid sequence of SEQ ID NO: 8 (as described in International PCT Publication No. WO 2012 / 145596, which is herein incorporated by reference in its entirety).
[0176] As used herein, the Trichoderma sp. "GAS1 protein" comprises the amino acid sequence of SEQ ID NO:9 (as described in International PCT Publication Nos. WO 2012 / 145596 and WO 2012 / 145592, each of which is herein incorporated by reference in its entirety).
[0177] As used herein, the Trichoderma sp. "TSP2 protein" comprises the amino acid sequence of SEQ ID NO: 10 (as described in International PCT Publication No. WO 2012 / 145598, which is herein incorporated by reference in its entirety).
[0178] As used herein, the wild-type "ssb7 gene" encodes a native "SSB7 protein" described in International PCT Application Serial No. PCT / US2019 / 27590 filed on April 16, 2019. For example, the wild-type Trichoderma reesei "ssb7 gene" (SEQ ID NO: 20) encodes a native "SSB7 protein" of SEQ ID NO: 21.
[0179] As used herein, "allele ssb7(fs)" (SEQ ID NO:22) encodes a variant SSB7 protein of SEQ ID NO:23, as described in International PCT Application Serial No. PCT / US2019 / 27590 (specifically incorporated herein by reference in its entirety).
[0180] II. Filamentous Fungal Strains Containing an Enhanced Protein Productivity Phenotype
[0181] As generally described above and further described in the Examples section below, certain embodiments of the present disclosure relate to mutations and genetically modified (variants) strains of filamentous fungi derived from parental strains. More particularly, certain embodiments relate to mutations and genetically modified (variants) strains of filamentous fungi (and methods thereof), wherein such strains comprise protein productivity-enhancing phenotypes, such as improved volumetric efficiency, higher specific productivity, improved carbon source yield, reduced bioreactor (fermenter) operating costs, etc.
[0182] More specifically, as further described in Example 1 below, a mutant (progeny) Trichoderma strain was identified, isolated and named "B7ms1-SF12" that had a 40% higher protein yield on a fed sugar in a fermentor relative to the parent strain (B7ms1) from which it was derived (e.g., see Figure 1). The mutant B7ms1-SF12 strain was subsequently subjected to genomic sequence analysis and genetic analysis to identify one or more mutations in one or more genes that cause the observed (increased productivity) phenotype of the B7ms1-SF12 (mutant) strain. More specifically, it was determined that the identified mutations were able to alter the coding sequence of the (native) LOV protein of SEQ ID NO:2, wherein the highly conserved threonine (T) (T813) at amino acid (residue) position 813 of the (native) LOV protein (SEQ ID NO:2) was mutated (substituted) to lysine (813K) at position 813 of the (variant) LOV protein of SEQ ID NO:4 (i.e., T813K substitution; see, for example, Figure 2 ).
[0183] A review of the scientific literature and related art indicates that the functional characterization of the LOV protein (SEQ ID NO: 2) and / or related LOV protein orthologs (e.g., SEQ ID NOs: 11-17) from any organism has not been described in the literature. However, as generally described in Example 1 of the present disclosure, conserved domain analysis (NCBI) identified a glycosyltransferase family 2 group (pfam13632, E value 3.25x10-44, see e.g. Figure 2 "Glyco trans 2 3" distantly related (conserved) regions in. For example, members of this (glycosyltransferase) family of prokaryotic proteins include putative glucosyltransferases that are involved in bacterial capsule biosynthesis (PFAM). More specifically, the fungal protein "ZtGT2" with a (glycosyltransferase) family 2 group domain, which is orthologous to Trichoderma PID 79396 (i.e., it is not LOV, PID 50212), is important for hyphal growth on solid surfaces (King et al., 2017).
[0184] Most surprisingly, the LOV protein is widely conserved among filamentous fungi of the phyla Basidiomycota and Ascomycota. For example, in the top BLASTp search results of the NCBI non-redundant database, the threonine (T) at position 813 of the (native) LOV protein (i.e., its mutation to lysine (K) is beneficial as disclosed herein) is highly conserved (691 / 691; 100%) in the subphylum Pezizomycotina, to which Trichoderma and most industrially relevant filamentous fungi belong. For example, a graphical representation of the Geneious multiple sequence alignment (www.geneious.com, Geneious 11.0, Biomatters Ltd.) from these 691 Pezizomycotina homologs is shown in Figure 1. Figure 2Likewise, in the MUSCLE multiple sequence alignment (Genetic software package), in the top 1,000 BLASTp hits, amino acid residue position 813 is identical in 975 / 1000 (97.5%) of the hits (i.e., residue T813), wherein lysine (K) never occurs at residue position 813 (i.e., the substitutions described herein that result in increased protein productivity are not found in the top 1000 orthologs identified by BLASTp).
[0185] Therefore, to further verify that the lov(T813K) allele is responsible for the observed increased protein productivity phenotype, the lov(T813K) mutation was introduced into a different T. reesei strain lineage named "T4" (e.g., see Table 1), where both the B7ms1 and T4 parental lines are mutagenesis derivatives of different strain improvement programs of Trichoderma strain RL-P37 (Sheir-Neiss et al., 1984; Montenecourt, 1987). For example, the T4 strain differs significantly from the B7ms1 strain in that the T4 strain expresses its (endogenous) natural mixture of cellulases and contains a nik1(M743T) mutation that increases total protein production (e.g., see International PCT Publication No. WO 2016 / 130523). Likewise, similar to the observations for the B7ms1 lineage described in Example 1, the total protein yield of the fed sugar by the T4 lineage (strain) containing the lov(T813K) allele (e.g., see Examples 2 and 4) was increased by an average of 34% relative to the isogenic strain containing the wild-type lov(+) allele.
[0186] Additionally, to further demonstrate the utility of the lov(T813K) allele for improving the protein productivity phenotype of fungal strains, Applicants integrated the pyr2 marker at three other convenient genomic locations (i.e., designated sites AC; see also Example 4, Tables 1 and 2). Protein production by these various strains was evaluated, for example, in shake flasks, where in all such cases, the presence of the lov(T813K) mutation improved total protein production relative to the original isogenic (parental) strain containing the wild-type lov(+) allele.
[0187] III. Molecular Biology
[0188] As generally described above, certain embodiments of the present disclosure relate to mutations and genetically modified (variants) strains of filamentous fungi derived from parental strains. More particularly, certain embodiments relate to mutations and genetically modified (variants) strains of filamentous fungi (and methods thereof), wherein such strains comprise protein productivity-enhancing phenotypes, such as improved volumetric efficiency, higher specific productivity, improved carbon source yield, reduced bioreactor (fermenter) operating costs, etc.
[0189] Therefore, certain embodiments of the present disclosure relate to a mutant (offspring) Trichoderma strain (e.g., mutant B7ms1-SF12) derived from a parent Trichoderma strain (e.g., parent B7ms1), wherein the mutant (offspring) Trichoderma strain comprises a mutant lov gene encoding a variant LOV protein, wherein the variant LOV protein comprises a lysine (K) residue at the amino acid position corresponding to amino acid residue position 813 of SEQ ID NO:4.
[0190] Therefore, certain other embodiments of the present disclosure relate to genetically modified strains of filamentous fungi derived from the parent strains described herein (hereinafter "variant" strains). For example, in certain embodiments, the variant strain of filamentous fungi comprises a modified lov gene (or a modified polynucleotide sequence thereof) encoding a variant LOV protein, the variant LOV protein having sequence homology to SEQ ID NO:2 (i.e., a native LOV protein sequence), and the variant strain of filamentous fungi comprises a lysine (K) residue at the amino acid sequence position corresponding to amino acid position 813 of SEQ ID NO:4.
[0191] Thus, in certain embodiments, the variant strains of the present disclosure comprise a modified lov gene (or a modified polynucleotide sequence thereof) encoding a LOV protein having at least about 50% to about 100% sequence homology with the LOV protein of SEQ ID NO:2 (or SEQ ID NO:4) and comprising a lysine (K) residue at the amino acid sequence position corresponding to amino acid position 813 of SEQ ID NO:4. In certain embodiments, the variant strains of the present disclosure comprise a modified lov gene (or a modified polynucleotide sequence thereof) encoding a LOV protein having at least about 50% to about 100% sequence homology with the LOV protein of SEQ ID NO:2 (or SEQ ID NO:4) and comprising a lysine (K) residue at the amino acid sequence position corresponding to amino acid position 813 of SEQ ID NO:4.
[0192] Thus, in other embodiments, the variant strains of the present disclosure comprise a modified lov gene (or a modified polynucleotide sequence thereof) encoding a LOV protein having at least about 50% sequence homology or identity to SEQ ID NO:2 or SEQ ID NO:4, at least about 55% sequence homology or identity to SEQ ID NO:2 or SEQ ID NO:4, at least about 60% sequence homology or identity to SEQ ID NO:2 or SEQ ID NO:4, at least about 65% sequence homology or identity to SEQ ID NO:2 or SEQ ID NO:4, at least about 70% sequence homology or identity to SEQ ID NO:2 or SEQ ID NO:4, at least about 75% sequence homology or identity to SEQ ID NO:2 or SEQ ID NO:4, at least about 80% sequence homology or identity to SEQ ID NO:2 or SEQ ID NO:4, at least about 85% sequence homology or identity to SEQ ID NO:2 or SEQ ID NO:4, at least about 90% sequence homology or identity to SEQ ID NO:2 or SEQ ID NO:4, NO:2 or SEQ ID NO:4 has at least about 90% sequence homology or identity, has at least about 95% sequence homology or identity with SEQ ID NO:2 or SEQ ID NO:4, or has up to and is about 100% sequence homology or identity with SEQ ID NO:2 or SEQ ID NO:4, and comprises a lysine (K) residue at the amino acid sequence position corresponding to amino acid position 813 of SEQ ID NO:4.
[0193] Therefore, in certain embodiments, the variant strain of filamentous fungi at least comprises a genetic modification that introduces the allele lov (T813K) into the strain. For example, in certain embodiments, the variant strain of filamentous fungi may comprise the following genetic modifications, including but not limited to: (a) introducing, replacing or removing one or more nucleotides in a gene (or ORF or its polynucleotide), or introducing, replacing or removing one or more nucleotides in a regulatory element required for transcription or translation of a gene, (b) gene disruption, (c) gene transformation, (d) gene deletion, (e) gene downregulation, (f) specific mutagenesis and / or (g) random mutagenesis. In other embodiments, the variant strain of filamentous fungi comprising the allele lov (T813K) further comprises one or more genetic modifications of genes encoding NIK1 protein, SSB7 protein, MPG1 protein, SFB3 protein, SEB1 protein, CRZ1 protein, TSP2 protein and / or GAS1 protein as described herein.
[0194] Therefore, in certain embodiments, a variant strain of a filamentous fungus comprising a genetic modification can be constructed by gene deletion to eliminate the expression / production of a given gene product (e.g., LOV (+), NIK1, SSB7, MPG1 SFB3, SEB1, CRZ1, TSP2, GAS1, endogenous (background) protease, cellulase, etc.). In other embodiments, a variant strain of a filamentous fungus comprising a genetic modification can be constructed by eliminating (or reducing) the expression / production of a given gene product by partial gene deletion. For example, in certain embodiments, the modified filamentous fungus strain can include a partial deletion of a gene, wherein the partial deletion includes a partial deletion of any part of the gene coding sequence. For example, in certain embodiments, such variant strains do not express / produce an encoded protein, or such variant strains express / produce a reduced amount of an encoded protein (relative to the parent strain), wherein the "reduced" amount of the encoded protein can be measured, detected, determined, etc. as described herein.
[0195] Thus, as generally illustrated and described in the Examples section, one skilled in the art can perform the following genetic modifications (and the molecular biological methods thereof described in this section) and construct such (variant) filamentous fungal strains thereof by reference to one or more amino acid sequences (SEQ ID NOs: 2, 4, 11-19) and / or nucleic acid sequences (SEQ ID NOs: 1 and 2) of the present disclosure.
[0196] For example, gene deletion technology can partially or completely remove gene, thereby eliminate or reduce protein expression / generation, and / or thereby eliminate or reduce the expression / generation of encoded protein.In this type of method, the deletion of gene can be completed by using integration plasmid / vector to carry out homologous recombination, and described integration plasmid / vector has been constructed into 5 ' and 3 ' districts that contain gene flank continuously.Can be by continuous 5 ' and 3 ' district for example on integration plasmid / vector, under being combined with selectable marker, introduce into filamentous fungal cell to allow plasmid to be integrated in cell.
[0197] In other embodiments, the variant strain of filamentous fungi comprises a genetic modification that destroys or inactivates a gene encoding a protein disclosed herein. An exemplary method of gene disruption / inactivation includes destroying any part of a gene, including a polypeptide coding sequence (CDS), a promoter, an enhancer, or another regulatory element, and the disruption includes substitution, insertion, deletion, inversion, and combinations thereof and variants thereof. Therefore, in certain embodiments, a variant strain of filamentous fungi is constructed by gene disruption techniques. The non-limiting example of gene disruption techniques includes inserting (integrating) an integration plasmid containing a nucleic acid fragment homologous to the gene into one or more genes disclosed herein, which will produce repetitions of homologous regions, and incorporating (inserting) vector DNA between the repeated regions.
[0198] Therefore, in some other non-limiting examples, gene disruption techniques include inserting into a gene an integration plasmid containing a nucleic acid fragment homologous to the gene, which will produce a repetition of homologous regions, and incorporating (inserting) vector DNA between the repeated regions, wherein the inserted vector DNA separates, for example, the promoter of a gene from a protein coding region, or interrupts (disrupts) the coding or non-coding sequence of a gene. Therefore, the disruptive construct can be a selectable marker gene (e.g., pyr2; see examples) with 5' and 3' regions homologous to the gene. Selectable markers enable identification of transformants containing disrupted genes. Therefore, in certain embodiments, gene disruption includes modification of the following gene control elements, such as promoters, ribosome binding sites (RBS), untranslated regions (UTRs), codon changes, etc.
[0199] In other embodiments, variant strains of filamentous fungi are constructed (i.e., genetically modified) by introducing, replacing or removing one or more nucleotides in a gene or a regulatory element required for transcription or translation thereof. For example, nucleotides may be inserted or removed to introduce a stop codon, remove a start codon or shift an open reading frame (ORF). Such modifications may be accomplished by site-directed mutagenesis or PCR-generated mutagenesis according to methods known in the art (e.g., see Botstein and Shortle, 1985; Lo et al., 1985; Higuchi et al., 1988; Shimada, 1996; Ho et al., 1989; Horton et al., 1989 and Sarkar and Sommer, 1990). Similarly, allele lov (T813K) comprising the T813K substitution described herein may be constructed by replacing the nucleotides encoding the 813 lysine at position 813 of the wild-type lov (+) gene with the nucleotides encoding the 813 threonine at position 813 of the allele lov (T813K).
[0200] In other embodiments, variant strains of filamentous fungi are constructed (i.e., genetically modified) by the process of gene transformation (e.g., see Iglesias and Trautner, 1983). For example, in a gene transformation method, a nucleotide sequence corresponding to a target gene is induced in vitro to produce a defective nucleotide sequence, which is then transformed into a parental cell to produce a variant cell comprising a defective gene. By homologous recombination, the defective nucleotide sequence replaces the endogenous gene. It may be desirable that the defective gene or gene fragment also encodes a marker that can be used to select a transformant containing the defective gene. For example, the defective gene can be combined with a selectable marker and introduced into a non-replicating or temperature-sensitive plasmid. The selection of plasmid integration is achieved by selecting a marker under conditions that do not allow plasmid replication. The second recombination event that causes gene replacement is selected by checking the colony for loss of selectable markers and obtaining mutant genes (Perego, 1993).
[0201] In other embodiments, variant strains of filamentous fungi are constructed by established antisense (gene silencing) techniques using nucleotide sequences complementary to the nucleotide sequence of the gene (Parish and Stoker, 1997). More specifically, the expression of the gene of the filamentous fungal strain can be reduced (downregulated) or eliminated by introducing a nucleotide sequence complementary to the nucleotide sequence of the gene, which is transcribed in the cell and can hybridize with the mRNA produced in the cell. Under conditions where the complementary antisense nucleotide sequence is allowed to hybridize with the mRNA, the amount of the translated protein is thereby reduced or eliminated. Such antisense methods include, but are not limited to, RNA interference (RNAi), small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, etc., all of which are well known to those skilled in the art.
[0202] In other embodiments, variant strains of filamentous fungi are constructed (i.e., genetically modified) by random or specific mutagenesis using methods well known in the art, including but not limited to chemical mutagenesis (see, e.g., Hopwood, 1970) and transposition (see, e.g., Youngman et al., 1983). Modification of the gene can be performed by mutagenizing the parental cells and screening for mutant cells in which gene expression has been reduced or eliminated. For example, one skilled in the art can readily modify and / or adapt the screening methods set forth in the Examples section herein to identify such (mutagenized) variant strains of filamentous fungal cells comprising a reduced viscosity phenotype.
[0203] Mutagenesis can be specific or random, and can be carried out by, for example, using a suitable physical or chemical mutagen, by using a suitable oligonucleotide or by subjecting the DNA sequence to mutagenesis produced by PCR. In addition, mutagenesis can be carried out by using any combination of these mutagenesis methods. Examples of physical or chemical mutagens suitable for the purpose of the present invention include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), N-methyl-N'-nitrosoguanidine (NTG), o-methylhydroxylamine, nitrous acid, ethyl methanesulfonic acid (EMS), sodium bisulfite, formic acid and nucleotide analogs. When using these reagents, mutagenesis is typically carried out by the following method: incubate the parental cell to be mutated under suitable conditions in the presence of the mutagen selected, and select mutant cells showing reduced or no gene expression.
[0204] For example, such genetic modifications of one or more genes disclosed herein can reduce the efficiency of a gene promoter, reduce the efficiency of an enhancer, interfere with splicing or editing of a gene mRNA, interfere with translation of a gene mRNA, introduce a stop codon into a gene coding sequence to prevent translation of a full-length protein, alter the coding sequence of a protein to produce a less active or inactive protein, reduce protein interactions with other nuclear protein components, alter the coding sequence of a protein to produce a less stable protein or target the protein for destruction, or cause the protein to be misfolded or mismodified (e.g., by glycosylation), or interfere with cellular trafficking of the protein.
[0205] In certain other embodiments, variant strains of filamentous fungi (i.e., genetically modified) are constructed by means of site-specific gene editing techniques. For example, in certain embodiments, variant strains of filamentous fungi are constructed (i.e., genetically modified) by using transcriptional activators such as endonucleases (TALEN), zinc finger endonucleases (ZFN), homing (large) endonucleases, etc. More particularly, the portion to be modified in the gene (e.g., coding region, non-coding region, leader sequence, propeptide sequence, signal sequence, transcription terminator, transcriptional activator or other regulatory elements desired for expression coding region) are genetically modified by means of ZFN gene editing, TALEN gene editing, homing (large) endonucleases, etc., and the modification method is well known and available to those skilled in the art.
[0206] Therefore, in certain embodiments, variant strains of filamentous fungi are constructed (i.e., genetically modified) by means of CRISPR / Cas9 editing. More specifically, compositions and methods for modifying fungal genomes using CRISPR / Cas9 systems are described and known in the art (e.g., see International PCT Publication Nos.: WO 2016 / 100571, WO 2016 / 100568, WO 2016 / 100272, WO 2016 / 100562, etc.). For example, a gene encoding a natural LOV protein can be genetically modified by means of a nucleic acid-guided endonuclease, which finds its target DNA by binding to a guide RNA (e.g., Cas9) or a guide DNA (e.g., NgAgo), which recruits the endonuclease to a target sequence on the DNA, wherein the endonuclease can produce a single-strand or double-strand break in the DNA. This targeted DNA break becomes a substrate for DNA repair and can be recombined with a provided editing template to destroy or delete the gene. For example, a gene encoding a nucleic acid-guided endonuclease (e.g., a Cas9 from Streptococcus pyogenes (S. pyogenes) or a codon-optimized gene encoding a Cas9 nuclease) is operably linked to an active promoter in a filamentous fungal cell and an active terminator in a filamentous fungal cell, thereby producing a filamentous fungal Cas9 expression cassette. Similarly, one skilled in the art can easily identify one or more target sites specific to a gene of interest.
[0207] For example, in order to construct a DNA construct for a target site in a target gene encoding a gRNA, a variable targeting domain (VT) will include nucleotides of a target site adjacent to a motif (TGG) 5' of a (PAM) protospacer sequence, which are fused to a DNA encoding the Cas9 endonuclease recognition domain (CER) of Streptococcus pyogenes Cas9. The DNA encoding the VT domain and the DNA encoding the CER domain are combined to produce a DNA encoding a gRNA. Therefore, a filamentous fungus expression cassette of a gRNA is produced by effectively connecting the DNA encoding the gRNA to an active promoter in a filamentous fungal cell and an active terminator in a filamentous fungal cell.
[0208] In certain embodiments, DNA breaks induced by endonucleases are repaired / replaced with input sequences. For example, in order to accurately repair DNA breaks generated by the above-mentioned Cas9 expression cassette and gRNA expression cassette, a nucleotide editing template is provided so that the cell's DNA repair machinery can utilize the editing template. For example, about 500 bp 5' of the target gene can be fused to about 500 bp 3' of the target gene to generate an editing template, which is used by the machinery of the filamentous fungal host to repair DNA breaks generated by RGEN (RNA-guided endonuclease).
[0209] Cas9 expression cassette, gRNA expression cassette and editing template can be delivered to filamentous fungal cells together using many different methods (e.g., protoplast fusion, electroporation, natural competence or induced competence). By amplifying the target locus with forward and reverse primers, the transformed cells are screened by PCR. These primers can amplify the wild-type locus or the modified locus edited by RGEN. These fragments are then sequenced using sequencing primers to identify the edited bacterium colonies.
[0210] IV. Target protein
[0211] As briefly stated in the preceding section, the strains and methods of the present invention can be used to produce commercially important proteins in submerged cultures of filamentous fungi. The protein of interest (POI) disclosed herein can be any endogenous or heterologous protein, and it can be a variant of such a POI. The protein can contain one or more disulfide bridges, or be a protein whose functional form is a monomer or a polymer, i.e., the protein has a quaternary structure and is composed of multiple identical (homologous) or non-identical (heterologous) subunits, wherein the POI or its variant POI is preferably a POI having the desired properties.
[0212] In certain embodiments, the variant strain of filamentous fungi shows the protein titer of increase relative to (unmodified) parental strain, wherein protein titer is defined as the protein amount (g / L) of every volume.For example, titer can be measured by methods known in the art (for example, ELISA, HPLC, Bradford assay, LC / MS etc.).Therefore, in certain embodiments, compared to unmodified (parental) cell, the variant strain of filamentous fungi comprises at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9% or at least about 10% or more protein titer increase.
[0213] In certain embodiments, the variant strain of filamentous fungi shows the volume productivity of increase relative to (unmodified) parental strain, wherein volume productivity is defined as the amount (g) of protein produced by every total fermentation time of every nominal volume (L) bioreactor during fermentation. For example, the volume productivity can be measured by methods known in the art (for example, ELISA, HPLC, Bradford assay, LC / MS, etc.). Therefore, in certain embodiments, compared with unmodified (parental) cell, the variant strain of filamentous fungi comprises at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9% or at least about 10% or more volume productivity increase.
[0214] In certain other embodiments, the variant strain of the filamentous fungus exhibits an increased total protein yield, wherein the total protein yield is defined as the amount (g) of protein produced per gram of carbohydrate supply relative to the (unmodified) parent strain. Therefore, as used herein, the total protein yield (g / g) can be calculated using the following equation:
[0215] Y f =T p / T c
[0216] Among them, "Y f ” is the total protein yield (g / g), “T p ” is the total protein produced during fermentation (g), and “T c " is the total carbohydrates (g) fed during the fermentation (bioreactor) operation. In certain embodiments, the increase in total protein yield of the modified strain (i.e., relative to the parent strain) is at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10% or more compared to the unmodified (parent) cell.
[0217] Total protein yield can also be described as carbon conversion efficiency / carbon yield, for example, in the carbon supplied with the form of percentage (%) of incorporating total protein to describe.Therefore, in certain embodiments, the variant strain of filamentous fungi comprises the carbon conversion efficiency (for example, the increase of percentage (%) of incorporating total protein in the carbon supplied) increased relative to (unmodified) parental strain.In certain embodiments, the increase of the carbon conversion efficiency of the modified bacterial strain (that is, relative to the parental strain) is to increase at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9% or at least about 10% or more compared with unmodified (parental) cell.
[0218] In certain embodiments, the variant strain of the filamentous fungus exhibits an increased specific productivity (Qp) of the POI relative to the (unmodified) parent strain. For example, the detection of specific productivity (Qp) is a suitable method for evaluating protein production. Specific productivity (Qp) can be determined using the following equation:
[0219] “Qp=gP / gDCW·hr”
[0220] Wherein, "gP" is the grams of protein produced in the tank; "gDCW" is the grams of dry cell weight (DCW) in the tank, and "hr" is the fermentation time in hours from the inoculation time, which includes production time and growth time. Thus, in certain embodiments, the variant strain of the filamentous fungus comprises at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10% or more specific productivity (Qp) increase compared to unmodified (parent) cells.
[0221] In certain embodiments, the POI or a variant POI thereof is selected from the group consisting of acetylesterase, aminopeptidase, amylase, arabinase, arabinofuranosidase, carbonic anhydrase, carboxypeptidase, catalase, cellulase, chitinase, rennetinase, cutinase, deoxyribonuclease, epimerase, esterase, α-galactosidase, β-galactosidase, α-glucanase, glucan lyase, endo-β-glucanase, glucoamylase, glucose oxidase, α-glucosidase, β-glucosidase, glucuronidase, glycoside hydrolyzing enzyme. Enzymes, hemicellulases, hexose oxidases, hydrolases, invertases, isomerases, laccases, ligases, lipases, lyases, mannanases, mannosidases, oxidases, oxidases, oxidoreductases, pectate lyases, pectin acetylesterases, pectin depolymerases, pectin methylesterases, pectinolytic enzymes, perhydrolases, polyol oxidases, peroxidases, phenoloxidases, phytases, polygalacturonases, proteases, peptidases, rhamnogalacturonases, ribonucleases, transferases, transporters, transglutaminases, xylanases, hexose oxidases, and combinations thereof.
[0222] In certain embodiments, the POI or variant POI thereof is selected from an Enzyme Commission (EC) number selected from the group consisting of EC 1, EC 2, EC 3, EC 4, EC 5, or EC 6.
[0223] For example, in certain embodiments, the POI is an oxidoreductase, including but not limited to an EC1 (oxidoreductase) enzyme selected from the group consisting of EC 1.10.3.2 (e.g., laccase), EC 1.10.3.3 (e.g., L-ascorbate oxidase), EC 1.1.1.1 (e.g., alcohol dehydrogenase), EC 1.11.1.10 (e.g., chloride peroxidase), EC 1.11.1.17 (e.g., peroxidase), EC 1.1.1.27 (e.g., L-lactate dehydrogenase), EC 1.1.1.47 (e.g., glucose 1-dehydrogenase), EC 1.1.3.X (e.g., glucose oxidase), EC 1.1.3.10 (e.g., pyranose oxidase), EC 1.13.11.X (e.g., dioxygenase), EC 1.13.11.12 (e.g., linoleate 13S-lipoxygenase), EC EC 1.1.3.13 (e.g., alcohol oxidases), EC 1.14.14.1 (e.g., monooxygenases), EC 1.14.18.1 (e.g., monophenol monooxigenases), EC 1.15.1.1 (e.g., superoxide dismutases), EC 1.1.5.9 (formerly EC 1.1.99.10, e.g., glucose dehydrogenases), EC 1.1.99.18 (e.g., cellobiose dehydrogenases), EC 1.1.99.29 (e.g., pyranose dehydrogenases), EC 1.2.1.X (e.g., fatty acid reductases), EC 1.2.1.10 (e.g., acetaldehyde dehydrogenases), EC 1.5.3.X (e.g., fructosylamine reductases), EC 1.8.1.X (e.g., disulfide reductases), and EC 1.8.3.2 (e.g., thiol oxidases).
[0224] In certain embodiments, the POI is a transferase, including but not limited to an EC 2 (transferase) enzyme selected from the group consisting of EC 2.3.2.13 (e.g., transglutaminase), EC 2.4.1.X (e.g., hexosyltransferase), EC 2.4.1.40 (e.g., alternasucrase), EC 2.4.1.18 (e.g., 1,4 α-glucan branching enzyme), EC 2.4.1.19 (e.g., cyclomaltodextrin glucanotransferase), EC 2.4.1.2 (e.g., dextrin glucanase), EC 2.4.1.20 (e.g., cellobiose phosphorylase), EC 2.4.1.25 (e.g., 4-α-glucanotransferase), EC 2.4.1.333 (e.g., 1,2-β-oligoglucose phosphotransferase), EC EC 2.4.1.4 (e.g., amylosucrase), EC 2.4.1.5 (e.g., glucansucrase), EC 2.4.1.69 (e.g., galactoside 2-α-L-fucosyltransferase), EC 2.4.1.9 (e.g., inulinsucrase), EC 2.7.1.17 (e.g., xylulokinase), EC 2.7.7.89 (formerly EC 3.1.4.15, e.g., [glutamine synthetase]-adenosine-L-tyrosine phosphorylase), EC 2.7.9.4 (e.g., α-glucan kinase), and EC 2.7.9.5 (e.g., phosphoglucan kinase).
[0225] In other embodiments, the POI is a hydrolase, including but not limited to an EC 3 (hydrolase) enzyme selected from the group consisting of EC 3.1.XX (e.g., esterase), EC 3.1.1.1 (e.g., pectinase), EC 3.1.1.14 (e.g., chlorophyllase), EC 3.1.1.20 (e.g., tannase), EC 3.1.1.23 (e.g., glyceride acyl hydrolase), EC 3.1.1.26 (e.g., galactolipase), EC 3.1.1.32 (e.g., phospholipase A1), EC 3.1.1.4 (e.g., phospholipase A2), EC 3.1.1.6 (e.g., acetyl esterase), EC 3.1.1.72 (e.g., acetyl xylan esterase), EC 3.1.1.73 (e.g., ferulic acid esterase), EC 3.1.1.74 (e.g., cutinase), EC EC 3.1.1.86 (e.g., rhamnogalacturonate acetylesterase), EC 3.1.1.87 (e.g., fumonisin B1 esterase), EC 3.1.26.5 (e.g., ribonuclease P), EC 3.1.3.X (e.g., phosphomonoester hydrolase), EC 3.1.30.1 (e.g., Aspergillus nuclease S1), EC 3.1.30.2 (e.g., Serratia marcescens nuclease), EC 3.1.3.1 (e.g., alkaline phosphatase), EC 3.1.3.2 (e.g., acid phosphatase), EC 3.1.3.8 (e.g., 3-phytase), EC 3.1.4.1 (e.g., phosphodiesterase I), EC 3.1.4.11 (e.g., phosphatidylinositol phospholipase C), EC EC 3.1.4.3 (e.g., phospholipase C), EC 3.1.4.4 (e.g., phospholipase D), EC 3.1.6.1 (e.g., arylsulfatase), EC 3.1.8.2 (e.g., diisopropyl-fluorophosphatase), EC 3.2.1.10 (e.g., oligo-1,6-glucosidase), EC 3.2.1.101 (e.g., mannan endo-1,6-α-mannosidase), EC 3.2.1.11 (e.g., α-1,6-glucan-6-glucanohydrolase), EC 3.2.1.131 (e.g., xylan α-1,2-glucuronidase), EC 3.2.1.132 (e.g., chitosan N-acetylglucosaminyl hydrolase), EC 3.2.1.139 (e.g., α-glucuronidase), EC 3.2.1.14 (e.g., chitinase), EC 3.2.1.151 (e.g., xyloglucan-specific endo-β-1,4-glucanase), EC 3.2.1.155 (e.g., xyloglucan-specific exo-β-1,4-glucanase), EC 3.2.1.164 (e.g., endogalactan-1,6-β-galactosidase), EC 3.2.1.17 (e.g., lysozyme), EC 3.2.1.171 (e.g., rhamnogalacturonan hydrolase), EC 3.2.1.174 (e.g., rhamnogalacturonan rhamnohydrolase), EC 3.2.1.2 (e.g., β-amylase), EC 3.2.1.20 (e.g., α-glucosidase), EC 3.2.1.22 (e.g., α-galactosidase), EC 3.2.1.25 (e.g., β-mannosidase), EC 3.2.1.26 (e.g., β-fructofuranosidase), EC 3.2.1.37 (e.g., xylan 1,4-β-xylosidase), EC EC 3.2.1.39 (e.g., glucan endo-1,3-β-D-glucosidase), EC 3.2.1.40 (e.g., α-L-rhamnosidase), EC 3.2.1.51 (e.g., α-L-fucosidase), EC 3.2.1.52 (e.g., β-N-acetylglucosaminidase), EC 3.2.1.55 (e.g., α-N-arabinofuranosidase), EC 3.2.1.58 (e.g., glucan 1,3-β-glucosidase), EC 3.2.1.59 (e.g., glucan endo-1,3-α-glucosidase), EC 3.2.1.67 (e.g., galactan 1,4-α-galacturonidase), EC 3.2.1.68 (e.g., isoamylase), EC EC 3.2.1.7 (e.g., 1-β-D-fructan fructohydrolase), EC 3.2.1.74 (e.g., glucan 1,4-β-glucosidase), EC 3.2.1.75 (e.g., glucan endo-1,6-β-glucosidase), EC 3.2.1.77 (e.g., mannan 1,2-(1,3)-α-mannosidase), EC 3.2.1.80 (e.g., fructan β-fructosidase), EC 3.2.1.82 (e.g., exo-poly-α-galacturonidase), EC 3.2.1.83 (e.g., κ-carrageenanase), EC EC 3.2.1.89 (e.g., arabinogalactan endo-1,4-β-galactosidase), EC 3.2.1.91 (e.g., cellulose 1,4-β-cellobiosidase), EC 3.2.1.96 (e.g., mannosyl-glycoprotein endo-β-N-acetylglucosaminidase), EC 3.2.1.99 (e.g., arabinogalactan endo-1,5-α-L-arabinosidase), EC 3.4.XX (e.g., peptidase), EC 3.4.11.X (e.g., aminopeptidase), EC 3.4.11.1 (e.g., leucyl aminopeptidase), EC 3.4.11.18 (e.g., methionyl aminopeptidase), EC 3.4.13.9 (e.g., Xaa-Pro dipeptidase), EC 3.4.14.5 (e.g., dipeptidyl-peptidase IV), EC 3.4.16.X (e.g., serine-type carboxypeptidase), EC 3.4.16.5 (e.g., carboxypeptidase C), EC 3.4.19.3 (e.g., pyroglutamyl peptidase I), EC 3.4.21.X (e.g., serine endopeptidase), EC 3.4.21.1 (e.g., chymotrypsin), EC 3.4.21.19 (e.g., glutamyl endopeptidase), EC 3.4.21.26 (e.g., prolyl oligopeptidase), EC 3.4.21.4 (e.g., trypsin), EC 3.4.21.5 (e.g., thrombin), EC 3.4.21.63 (e.g., Aspergillus melleus protease), EC 3.4.21.65 (e.g., thermomycin), EC 3.4.21.80 (e.g., streptomycin A), EC EC 3.4.22.X (e.g., cysteine endopeptidases), EC 3.4.22.14 (e.g., actin), EC 3.4.22.2 (e.g., papain), EC 3.4.22.3 (e.g., ficin), EC 3.4.22.32 (e.g., stem bromelain), EC 3.4.22.33 (e.g., fruit bromelain), EC 3.4.22.6 (e.g., chymopapain), EC 3.4.23.1 (e.g., pepsin A), EC 3.4.23.2 (e.g., pepsin B), EC 3.4.23.22 (e.g., Cryophthora pepsin), EC 3.4.23.23 (e.g., Mucor pepsin), EC 3.4.23.3 (e.g., pepsin), EC 3.4.24.X (e.g., metalloendopeptidases), EC EC 3.5.1.2 (e.g., L-glutamine amidohydrolase), EC 3.5.1.3 (e.g., N-acetyl-L-alanine amidohydrolase), EC 3.5.1.4 (e.g., amidase), EC 3.5.1.44 (e.g., protein-L-glutamine amidohydrolase), EC 3.5.1.5 (e.g., urease), EC 3.5.1.6 (e.g., urease), EC 3.5.1.7 (e.g., urease), EC 3.5.1.8 (e.g., N-acyl-L-alanine amidohydrolase), EC 3.5.1.9 (e.g., N-acetyl-L-alanine amidohydrolase), EC 3.5.1.10 (e.g., N-acyl-L-alanine amidohydrolase), EC 3.5.1.11 (e.g., EC 3.5.1.52 (e.g., peptide-N(4)-(N-acetyl-β-glucosaminyl)asparagine amidase), EC 3.5.1.81 (e.g., N-acyl-D-amino acid deacylase), EC 3.5.4.6 (e.g., AMP deaminase), and EC 3.5.5.1 (e.g., nitrilase).
[0226] In other embodiments, the POI is a lyase, including but not limited to an EC 4 (lyase) enzyme selected from the group consisting of EC 4.1.2.10 (e.g., mandelonitrile lyase), EC 4.1.3.3 (e.g., N-acetylneuraminic acid lyase), EC 4.2.1.1 (e.g., carbonic anhydrase), EC 4.2.2.- (e.g., rhamnogalacturonan lyase), EC 4.2.2.10 (e.g., pectin lyase), EC 4.2.2.22 (e.g., pectin trisaccharide-lyase), EC 4.2.2.23 (e.g., rhamnogalacturonan endolyase), and EC 4.2.2.3 (e.g., mannose aldehyde-specific alginate lyase).
[0227] In certain other embodiments, the POI is an isomerase, including but not limited to an EC 5 (isomerase) enzyme selected from the group consisting of EC 5.1.3.3 (e.g., aldose 1-epimerase), EC 5.1.3.30 (e.g., D-psicose 3-epimerase), EC 5.4.99.11 (e.g., isomaltulose synthase), and EC 5.4.99.15 (e.g., (1→4)-α-D-glucan 1-α-D-glucosylmutase).
[0228] In yet other embodiments, the POI is a ligase including, but not limited to, an EC 6 (ligase) enzyme selected from the group consisting of EC 6.2.1.12 (eg, 4-coumarate:CoA ligase) and EC 6.3.2.28 (eg, L-amino acid α-ligase).
[0229] These and other aspects and embodiments of the strains and methods of the invention will be apparent to the skilled artisan in view of the present description and the following examples.
[0230] Examples
[0231] Certain aspects of the present disclosure may be further understood from the following examples, which should not be construed as limiting. Modifications of materials and methods will be apparent to those skilled in the art.
[0232] Example 1
[0233] lov gene identified as responsible for increased protein production in filamentous fungi
[0234] A. Overview
[0235] In this example, a reduced viscosity Trichoderma strain named "B7ms1" was specifically developed, i.e., a construct expressing glucoamylase (GA) to reduce the tendency to ball up under shake flask conditions. More specifically, a mutant (strain) of B7ms1 was identified, isolated, and named "B7ms1-SF12". The (mutant) B7ms1-SF12 strain had a 40% higher protein yield on the fed sugar in the fermentor relative to the B7ms1 (parent) strain (e.g., see Figure 1 ).
[0236] Therefore, as described herein, genome sequence analysis and genetic analysis were performed on the B7ms1-SF12 (mutant) strain to identify one or more mutations in one or more genes that cause the observed (increased productivity) phenotype of the B7ms1-SF12 (mutant) strain. As disclosed herein, it was determined that the identified mutations could alter the coding sequence of the (natural) LOV protein, wherein the highly conserved threonine (T) (T813) at amino acid (residue) position 813 of the (natural) LOV protein (SEQ ID NO: 2) was changed (substituted) to lysine (813K) at position 813 of the (variant) LOV protein (SEQ ID NO: 4, i.e., T813K substitution) (see Figure 2 ).
[0237] B. Development Strategy
[0238] Filamentous fungal species (e.g., Trichoderma species, Aspergillus species, Fusarium species, Penicillium species, Chrysosporium species, Cephalosporium species, Talaromyces species, Penicillium species, Neurospora species, Myceliophthora species, etc.) are aerobic fungi that typically produce thick, viscous fermentation broths when used in commercial / industrial fermentations. High fermentation (broth) viscosity typically reduces the transfer of dissolved oxygen (DO), thereby limiting the amount of cell mass and reducing the volumetric productivity that can be achieved in such aerobic filamentous fungal fermentations. For example, isolation of mutant strains of filamentous fungi with reduced viscosity resulted in mutant strains / cells that produced fermentation broths with lower viscosity, wherein fermentations using such reduced viscosity strains / cells can utilize more cell mass, thereby increasing protein productivity (e.g., see Applicant's International PCT Publication Nos. WO 2012 / 145584, WO 2012 / 027580, WO 2012 / 145595, WO 2012 / 145596, and WO 2012 / 145592). More specifically, when Applicant began combining certain viscosity-reducing mutations to generate strains with further reduced viscosity, it was surprisingly observed that certain viscosity (reduced) combinations (i.e., mutations) thereof seemed to be more prone to forming mycelial balls in shake flask assays.
[0239] More specifically, as contemplated herein, if the observed increased propensity to form mycelial balls in shake flasks can be scaled up to fermenters, Applicants seek to mitigate the aforementioned balling phenotype by means of directed development experiments. For example, without wishing to be bound by any particular theory, mechanism of action, or manner, it is contemplated herein that such a tendency to form mycelial balls may adversely affect the production of proteins and / or downstream processing of such proteins. Applicants therefore reasonably believe that "developed" mutants of these strains can be generated, screened, and isolated, wherein such developed strains comprise reduced mycelial balling propensity in shake flasks, fermenters, bioreactors, and the like.
[0240] For example, the culture of Trichoderma strain B7ms1 is grown in a shake flask containing complete complex medium for 12-24 hours, then through a sieve of 70 microns (μm). According to cell density, fresh medium is inoculated with circulating fluid, or the whole circulating fluid is transferred to a fresh shake flask. After incubation, the process is repeated for several weeks, and samples are collected occasionally, and then plated to separate possible mutants. According to the overall change of shake flask morphology (for example, the change of shake flask morphology, including but not limited to balling or mycelium agglomeration) (individually), isolated strains are visually screened. In addition, those isolated strains with more uniform growth in shake flasks are tested in shake flasks, and then the protein production in fermenter.
[0241] C. Isolation and characterization of Trichoderma mutant strain B7ms1-SF12
[0242] In the above development scheme, the applicant isolated a mutant strain named "B7ms1-SF12", wherein the (mutant) B7ms1-SF12 strain exhibited higher protein production in shake flasks relative to the (parental) B7ms1 strain (data not shown). Therefore, regardless of any effect on the above-mentioned spheroidization phenotype, any one or more mutations that improve the protein production phenotype of the host strain are of particular value in terms of their potential to reduce fermentation / protein production costs.
[0243] Therefore, the total protein production of the (parent) B7ms1 strain and the spontaneous mutant (progeny) strain B7ms1-SF12 in a fermentor was determined. These strains were grown under the same conditions in submerged (liquid culture) and their total protein yields fed with sugars were compared in a 14 L fermentor. Figure 1 As shown, the mutant B7ms1-SF12 strain ( Figure 1 ; black line / black squares) shows that the yield improvement of the supplied sugars was increased by 44% relative to the (parental) B7ms1 strain ( Figure 1 ; grey line / grey square).
[0244] In brief, spores of each strain were added to 500 mL of culture medium in a 3L flask with both side and bottom baffles. The culture was grown in a shaking incubator at 34°C in minimal medium for 48 hours. After 48 hours, the contents of each flask were added to a 14L fermentor containing 9.5L culture medium, which contained 4.7 g / L KHPO, 1.0 g / L MgSO7HO, 4.3 g / L (NH)SO and 2.5 mL / L 400X Trichoderma reesei trace element solution (citric acid (anhydrous), 175 g / L; FeSO4·7H2O, 200 g / L, ZnSO4·7H2O, 16 g / L, CuSO4·5H2O, 3.2 g / L; MnSO4H2O, 1.4 g / L; H3BO3, 0.8 g / L). These components were heat sterilized together at 121°C for 30 minutes. Solutions of 60% glucose and 0.48% CaCl2·2H2O were autoclaved, cooled and added to the fermenter to a final concentration of 75 g / L glucose and 0.6 g / L CaCl2·2H2O. The medium was adjusted to pH 3.5 with 28% NH and the temperature was maintained at 34°C during growth. Once glucose was exhausted, the temperature was reduced to 28°C and glucose-sophorose was supplied to the culture. Dry cell weight (DCW), total protein concentration and other parameters were measured and the specific total protein production rate and the yield of the supplied sugar were calculated.
[0245] D. Identification of the causal lov(T813K) mutation in the Trichoderma mutant strain B7ms1-SF12
[0246] Applicants sequenced the genomes of the (parent) B7ms1 strain and the (mutant) B7ms1-SF12 (progeny) strain, thereby identifying two (2) new mutations that are expected to alter coding sequences in the B7ms1-SF12 genome, any of which alone (or in combination) may be necessary for the observed protein productivity (improvement) phenotype. More specifically, to determine / identify which of these mutations are important, a complementation analysis was used by transforming the (mutant) B7ms1-SF12 strain with DNA encoding each wild-type locus. For example, only one locus complemented the mutant phenotype upon transformation, and the locus was referred to as lov. The lov gene encodes a predicted protein PID 50212 (SEQ ID NO: 2), wherein in the (mutant) B7ms1-SF12 strain, the lov mutant (allele) comprises a single nucleotide change from G (guanine) to T (thymine) at position 425393 on scaffold sequence 16, resulting in an amino acid substitution T813K in the encoded LOV (variant) protein (SEQ ID NO: 4), the mutant allele being referred to herein as the allele "lov(T813K)", and the natural (wild-type) allele being referred to herein as "lov(+)".
[0247] Functional characterization of LOV proteins or LOV protein orthologs from any organism has not been described in the literature. As described herein, conserved domain analysis (NCBI) identified a glycosyltransferase family 2 group (pfam13632, E value 3.25x10-44, see e.g. Figure 2 "Glyco trans 2 3" distantly related (conserved) regions in. For example, members of this (glycosyltransferase) family of prokaryotic proteins include putative glucosyltransferases that are involved in bacterial capsule biosynthesis (PFAM). More specifically, the fungal protein "ZtGT2" with a (glycosyltransferase) family 2 group domain, which is orthologous to Trichoderma PID 79396 (i.e., it is not LOV, PID 50212), is important for hyphal growth on solid surfaces (King et al., 2017).
[0248] Most surprisingly, LOV proteins are widely conserved among filamentous fungi of the phyla Basidiomycota and Ascomycota. For example, in the top BLASTp search results of the NCBI non-redundant database, the threonine (T) at position 813 of the (native) LOV protein (i.e., its mutation to lysine (K) is beneficial as disclosed herein) is highly conserved (691 / 691; 100%) in the subphylum Pezizomycotina, to which Trichoderma and most industrially relevant filamentous fungi belong. A graphical representation of a Geneious multiple sequence alignment (www.geneious.com, Geneious 11.0, Biomatters Ltd.) from these 691 Pezizomycotina homologs is shown in Figure 1. Figure 2 Similarly, in the MUSCLE multiple sequence alignment (Genetic software package), residue position 813 was identical (i.e., T813) in 975 / 1000 (97.5%) of the top 1,000 BLASTp hits, with lysine (K) never occurring at residue 813 (i.e., the substitutions described herein that resulted in improved protein productivity were not found in the top 1000 orthologs identified by BLASTp). Although the conserved position and mutations could be used to improve fungal protein production, the T813 residue is not within any region previously annotated in Genebank ( Figure 2 ). The LOV protein is the only predicted member of this class of proteins in the Trichoderma genome, while many genomes have more than one predicted member.
[0249] Example 2
[0250] Targeted introduction of the lov(T813K) allele in a strain with reduced viscosity increases protein productivity in fermenters
[0251] A. Overview
[0252] To further verify that the lov(T813K) allele was responsible for the observed improvement in protein productivity, the lov(T813K) mutation was introduced into different strains of Trichoderma reesei (referred to herein as "T4"). Both the B7ms1 (Example 1) and T4 strains are mutagenesis derivatives of different strain improvement programs from Trichoderma strain RL-P37 (Sheir-Neiss et al., 1984; Montenecourt, 1987). The T4 strain differs significantly from the B7ms1 in that the T4 strain expresses a natural mixture of cellulases and contains a nik1(M743T) mutation that increases total protein production (US20180037919). As with the previous B7ms1 strain (Example 1), double mutants with reduced viscosity (Δmpg1; Δseb1) were generated in both T4 strains in the presence or absence of the lov(T813K) allele. For example, in fermentors, the total protein yield of the T4Δmpg1;Δseb1 strain containing the lov(T813K) allele was on average 37% higher on the fed sugars.
[0253] B. Construction of plasmids containing the lov disruption cassette with the pyr4 or pyr2 selection marker
[0254] The Trichoderma lov destruction box plasmid is prepared using standard molecular biology procedures, and the technicians in the relevant field can easily rebuild this plasmid according to the information disclosed herein. The plasmid includes a DNA sequence with a 1.6Kb homology box, which is identical to the DNA sequence corresponding to the support sequence 16426947 to 425393 (left flank). The last nucleotide of the left flank introduces a mutation in which a single nucleotide is changed from G to T, which corresponds to the mutation identified in the (mutation) B7ms1-SF12 bacterial strain (Example 1). The plasmid also includes a DNA sequence with a 1.5Kb homology box, which is identical to the DNA sequence corresponding to the support sequence 16 425392 to 423880 (right flank). These sequences are designed to target the lov gene, and the nucleotides (support sequence 16, 425393) of the genome between the left flank and the right flank are replaced with the inserted box sequence.
[0255] Such insert (cassette) sequences include the pyr4 selection marker from Trichoderma reesei (pRATT308) or the pyr2 selection marker from Trichoderma atroviride (pRATT312). Immediately downstream of the selection marker is a DNA sequence (repetitive sequence) with a 0.5 Kb region that is homologous to the 3' 0.5 Kb region of the left flank. These repetitive sequences are expected to promote subsequent deletion of the selection marker, so that this marker can be used in future strain development, and leave a single nucleotide mutation from G to T in the LOV gene encoding the LOV (T813K) protein (SEQ ID NO: 4) (scaffold sequence 16, 425393) as the only new targeted genome modification.
[0256] C. Development of T4 derivative strains with the lov(T813K) allele
[0257] Derivatives of the T4 strain, designated herein as strains "T4m" and "T4m_pyr2," were developed essentially as described in U.S. Pat. No. 9,725,727 (incorporated herein by reference in its entirety), and contain a viscosity-reducing disruption (Δmpg1) of the gene mpg1. Thus, the T4m_pyr2 strain (Δmpg1; pyr2) was transformed with the lov disruption cassette from pRATT312 (pyr2 selection marker) using PEG-mediated transformation and plated on Vogel minimal medium (Vogel, 1956) containing 1.2 M sorbitol to select candidate strains based on uridine prototrophy obtained by the pyr2 marker. Trichoderma transformation is well known and has been described in the art (e.g., see U.S. Pat. No. 5,246,853). Individual transformants were isolated and propagated by transfer to Vogel minimal medium. Transformants in which the lov disruption cassette was integrated at the lov locus by homologous recombination were identified using PCR analysis using methods known to those skilled in the art as follows.
[0258] Only a subset of recombinant cells can successfully utilize homologous flanks to correctly target the destruction of the target gene, so it may be necessary to screen many transformants to identify transformants with the desired event. PCR can be used to test which recombinant cells have the desired targeted destruction. Primers for amplification in each homology box region must be designed, one of which starts at a position greater than 100bp from the closest end within the selectable marker, and other primers start at a position greater than 100bp beyond the end of the homology box region within the adjacent genomic sequence. Cells that may contain the correct targeted destruction will successfully establish PCR products that span the left and right flanks of the destruction box, while failed transformation events will not produce products of the expected size. At this stage, the culture may be a mixture of transformed and untransformed cells, so a purification step may be required. The purification of the culture can be tested for the absence of a short PCR product spanning the destruction site by PCR.
[0259] More specifically, a strain of such a T4m derivative strain containing a pyr2 disruption of the lov gene was identified, isolated, and named "T4ml+" (i.e., containing the allele lov(dis) as opposed to the allele lov(T813K) encoding the specific T813K substitution). Therefore, to generate a strain containing the specific lov(T813K) allele, a spore suspension of strain T4ml+ (containing the lov(dis) allele) was plated on a medium containing 5-fluoroorotic acid (FOA) to select for derivative strains in which spontaneous recombination occurred between the repeat regions flanking the inserted selectable marker, accompanied by the deletion of the selectable marker from the genome. Uridine auxotrophs were isolated and analyzed by PCR to test for the absence of the selectable marker, and sequencing of the PCR products to confirm the presence of the lov(T813K) allele. In this manner, a strain containing the lov(T813K) allele was generated and is referred to herein as "T4ml". To restore pyrimidine prototrophy for fermentor evaluation, the pyr2 marker of both strains, T4ml and T4m_pyr2, was targeted to the viscosity-reducing locus seb1, essentially as described in U.S. Pat. No. 9,725,727, resulting in strains referred to herein as "T4mls" (comprising the lov(T813K) allele) and "T4ms" (comprising the lov(+) allele).
[0260] D. Fermenter evaluation of T4 derivative strains containing the lov(T813K) allele
[0261] Therefore, strains T4mls (comprising the lov(T813K) allele) and T4ms (comprising the lov(+) allele) were evaluated in fermentors as described in Example 1. In addition, the T4mls and T4ms strains were evaluated at lower cell density fermentations relative to Example 1 by adjusting the amount of glucose provided before the start of the feed to ensure that the protein production phenotype observed with the lov(T813K) allele was not limited to higher cell density fermentations. Figure 3 As shown, at lower cell density (LCD; Figure 3 , T4mls, black circles / black dashed line; T4ms, gray circles / gray dashed line) fermentation conditions with higher cell density (HCD; Figure 3 , T4mls, black squares / black solid line; T4ms, gray squares / gray solid line) fermentation conditions, when the lov(T813K) allele was present, the protein yield of the supplied sugar increased by 42% and 32%, respectively.
[0262] Example 3
[0263] Targeted disruption of the lov gene by insertion of the pyr2 selectable marker failed to improve productivity in fermenters
[0264] A. Overview
[0265] Given that the threonine (T) amino acid at residue 813 of the (native) LOV protein (SEQ ID NO: 2) is highly conserved, it seems likely that disruption of the locus in any manner that would block expression / production of the LOV protein would also improve the productivity of the strain. To test this hypothesis, fungal strains with and without the lov(dis) allele were compared in a fermentor, in which the pyr2 selection marker was inserted into the lov gene to disrupt LOV protein expression. Surprisingly, the lov(dis) allele did not improve production in the fermentor.
[0266] B. Fermenter evaluation of strains with the lov(dis) allele
[0267] The development of the T4m and T4ml+ strains was described above in Example 2. The strain T4ml+ is a derivative of T4m in which the pyr2 marker was inserted into the lov coding sequence of strain T4m_pyr2. The T4m and T4ml+ strains were evaluated under the same conditions in a 14 L fermentor, which was essentially the same as described in Example 1, but at a lower cell density fermentation, which was achieved by adjusting the amount of glucose provided before the feed was started.
[0268] Derivatives of T4 were developed essentially as described in U.S. Patent No. 9,725,727, and the derivatives were named "T4s" and "T4s_pyr2" (comprising a viscosity-reducing disruption of the gene seb1). The lov(dis) allele was introduced into T4s_pyr2 to produce strain T4sl+, similar to that described for strain T4m_pyr2 in Example 2. Therefore, the T4s and T4sl+ strains were evaluated in a 2L bioreactor under the same conditions. Specifically, for the 2L bioreactor, spores of each strain were added to 50mL of citrate minimal medium in a 250mL flask to produce a seed culture. The cultures were grown in a shaking incubator at 30°C and 170rpm for 48h. After 48 hours, 145.6mL of 50% glucose and 0.6g / kg of CaCl2 adjusted to pH 3.5 were inoculated with the seed culture. Thereafter, the temperature was maintained at 34°C and the pH was maintained at 3.5. After the batch glucose was exhausted, the glucose-sophorose feed was then introduced, the temperature was lowered to 25°C, and the pH was increased to 4.8. Dry cell weight (DCW), total protein concentration, and other parameters were measured, and the specific total protein production rate and the yield of the supplied sugars were calculated. Figure 4 As shown, when the lov(dis) mutation was present in the T4m background, protein yield from the supplied sugar was reduced by 17%, whereas there was no change when present in the T4s background.
[0269] Example 4
[0270] Targeted introduction of the lov(T813K) allele into other fungal strains improves protein productivity
[0271] A. Overview
[0272] In Example 2, the pyr2 auxotrophy associated with the production of the allele lov(T813K) and the marker deletion was restored by integrating the pyr2 marker at the seb1 locus. Thus, the improvement in protein production observed with the lov(T813K) allele was already demonstrated in Examples 1 and 2 in strains that always contained both mpg1 and seb1 viscosity mutations. To demonstrate the more general application of the lov(T813K) allele for improving strain productivity, the pyr2 marker was integrated into three other convenient genomic locations: site A, site B, and site C. Protein production of these different strains was evaluated in shake flasks, where in all cases the presence of the lov(T813K) mutation improved total protein production relative to the isogenic strain with the wild-type lov(+) allele. In contrast, strains containing the lov(dis) mutation did not show significant improvement in protein production in shake flasks.
[0273] B. Restoration of pyrimidine auxotrophy in T4ml and T4sl by targeted integration of the pyr2 selectable marker at different genomic locations
[0274] Using methods known to those skilled in the art, strains with or without the lov(T318K) allele were transformed independently with cassettes that targeted integration of pyr2 into three convenient genomic locations named site AC. In brief, after PEG-mediated transformation with the pyr2 cassette, protoplasts were plated on Vogel minimal medium containing 1.2M sorbitol to select candidate genes based on the uridine prototrophy obtained by the pyr2 marker. Individual transformants were isolated and propagated by transfer to Vogel minimal medium. PCR analysis was used to identify transformants with the pyr2 cassette integrated at the expected genomic location. After spore purification, further PCR analysis was performed to ensure that integration occurred correctly and that the transformant was homonuclear.
[0275] Thus, the pyr2 marker was integrated at site A, site B and site C in the pyr2 mutant strains T4m_pyr2 (lov(+)) and T4ml (Δmpg1; lov(T318K)), as described in Example 2 (see Table 1). Similarly, the pyr2 marker was integrated at site A in the mutant strains T4s_pyr2 (Δseb1; lov(+)) and T4sl (Δseb1; lov(T318K)), as described in Example 3. In addition, the disrupted allele lov(dis) was added to the full cellulase strains T4_pyr2 (pyr2; lov(+)) and 41G_pyr4 (pyr4; lov(+)) using plasmids pRATT312 and pRATT308, respectively, as described in Example 2.
[0276] C. Shake flask evaluation of strains with and without lov(T813K) or lov(dis) alleles
[0277] The protein production of the strains was evaluated in shake flask fermentation. Table 1 lists the strains evaluated. In all genetic backgrounds tested, when the lov(T813K) allele was present, the total protein titer increased. However, disruption of the lov gene lov(dis) allele with pyr4(41G) or pyr2 markers (T4 and T4m) did not show a significant improvement in relative titer.
[0278] Liquid defined (LD) medium (see, e.g., U.S. Pat. No. 8,455,631) contains the following components. Caseinoic acid, 9 g / L; (NH4)2SO4, 5 g / L; MgSO4·7H2O, 1 g / L; KH2PO4, 4.5 g / L; CaCl2·2H2O, 1 g / L, PIPPS, 33 g / L, 400× Trichoderma reesei trace elements, 2.5 ml / L; pH adjusted to 5.5 with NaOH. After sterilization, lactose or glucose / sophorose mixture was added to a final concentration of 1.6 w / v%.
[0279] In order to produce seed culture, spores of each strain were added to 50mL of YEG (5g / L yeast extract, 22g / L glucose, H2O) in a 250mL flask. The culture was grown in a shaking incubator at 28°C and 200rpm for 36-48 hours. After incubation, 0.3mL seed culture was added to 50mL LD medium in a baffled shake flask. This production culture was grown for 5 days at 28°C and 180rpm. Cells were pelleted by centrifugation, and the supernatant was then collected to harvest secreted proteins. Protein was precipitated from the supernatant with an equal volume of trichloroacetic acid (TCA) and subsequently dissolved in 0.1N sodium hydroxide (NaOH). Total protein was then measured using BCA protein assay (ThermoFisher Scientific, Grand Island, NY, USA) according to the manufacturer's protocol. In all shake flask experiments, duplicate prototrophic T4 and T4m strains were included. BCA assay values were normalized to the mean of these controls run in parallel to minimize the effect of any week-to-week variation in total protein production efficiency.
[0280] like Figure 5 As shown, in addition to the T4ms background exemplified above in a bioreactor (Example 2), protein titer increased when the lov(T813K) mutation was present in the T4mc (site C), T4md (site B), T4mp (site A), and T4sp (site A) backgrounds. In contrast, the genetic backgrounds 41G, T4, and T4m, which contained insertions of the pyr2 marker or pyr4 marker that disrupted the lov gene (i.e., allele lov(dis)), did not show significant improvements in protein production in shake flasks.
[0281] D. Fermenter evaluation of strain T4mp with and without the lov(T813K) allele
[0282] One pair of these strains, T4mp and T4mlp (with pyr2 inserted at site A), was further evaluated in a 14 L fermentor as described in Example 1, but at a lower cell density. Figure 6 As shown, in the presence of the lov(T813K) allele, this genetic background showed a 28% increase in total protein production from supplied sugars.
[0283] References
[0284] PCT application serial number PCT / US 2019 / 27590
[0285] PCT International Publication No. WO 1992 / 06183
[0286] PCT International Publication No. WO 1992 / 06209
[0287] PCT International Publication No. WO 1992 / 06221
[0288] PCT International Publication No. WO 1998 / 15619
[0289] PCT International Publication No. WO 2002 / 12465
[0290] PCT International Publication No. WO 2005 / 028636
[0291] PCT International Publication No. WO 2006 / 074005
[0292] PCT International Publication No. WO 2012 / 027580
[0293] PCT International Publication No. WO 2012 / 145584
[0294] PCT International Publication No. WO 2012 / 145592
[0295] PCT International Publication No. WO 2012 / 145595
[0296] PCT International Publication No. WO 2012 / 145596
[0297] PCT International Publication No. WO 2012 / 145598
[0298] PCT International Publication No. WO 2016 / 100272
[0299] PCT International Publication No. WO 2016 / 100562
[0300] PCT International Publication No. WO 2016 / 100568
[0301] PCT International Publication No. WO 2016 / 100571
[0302] PCT International Publication No. WO 2016 / 130523
[0303] U.S. Patent No. 5,246,853
[0304] U.S. Patent No. 8,455,631
[0305] U.S. Patent No. 9,725,727
[0306] U.S. Patent Publication No. US 2018 / 0037919
[0307] Altschul et al., J. Mol. Biol. 215:403-10, 1990.
[0308] Altschul et al., Meth. Enzymol. 266:460-80, 1996.
[0309] Ausubel et al., "Current Protocols in Molecular Biology", Eds., John Wiley & Sons, Inc., 1995, sections 2, 4 and 6.
[0310] Botstein and Shortle,Science 229:4719,1985.
[0311] Church and Gilbert, "Genomic Sequencing", PNAS, USA, 81, 1991-1995, 1984.
[0312] Devereux et al., Nucleic Acids Res. 12:387-95, 1984.
[0313] Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915, 1989.
[0314] Higgins and Sharp,CABIOS 5:151-53,1989.
[0315] Higgins et al., Gene 73:237-244, 1998.
[0316] Higuchi et al., Nucleic Acids Research 16:7351,1988.
[0317] Ho et al.,Gene 77:61,1989.
[0318] Hopwood,The Isolation of Mutants in Methods in Microbiology(J.R.Norris and D.W.Ribbons,eds.)pp 363-433,Academic Press,New York,1970.
[0319] Horton et al.,Gene 77:61,1989.
[0320] Iglesias and Trautner,Molecular General Genetics 189:73-76,1983.
[0321] Karlin et al.,Proc.Natl.Acad.Sci.USA 90:5873-87,1993.
[0322] King et al.,“A conserved fungal glycosyltransferase facilitatespathogenesis of plants by enabling hyphal growth on solid surfaces”,PLoSPathology,13(10),1-26,2017.
[0323] Lo et al.,Proceedings of the National Academy of Sciences USA 81:2285,1985.
[0324] Montenecourt B.S.,Can.,1-20,1987.
[0325] Needleman and Wunsch,J.Mol.Biol.,48:443,1970.
[0326] Parish and Stoker,FEMS Microbiology Letters 154:151-157,1997.
[0327] Perego,1993,In A.L.Sonneshein,J.A.Hoch,and R.Losick,editors,Bacillussubtilis and Other Gram-Positive Bacteria,Chapter 42,American Society ofMicrobiology,Washington,D.C.
[0328] Sambrook et al.,“Molecular Cloning:A Laboratory Manual”,Cold SpringHarbor Press,Cold Spring Harbor,N.Y.(1989),chapters 7,9 and 11.
[0329] Sarkar and Sommer,BioTechniques 8:404,1990.
[0330] Sheir-Neiss et al.,Appl.Microbiol.Biotechnology,20:46-53,1984.
[0331] Shimada,Meth.Mol.Biol.57:157;1996.
[0332] Smith and Waterman,Adv.Appl.Math.2:482,1981.
[0333] The Genome Portal of the Department of Energy Joint Genome Institute,I.V.Grigoriev,H.Nordberg,I.Shabalov,A.Aerts,M.Cantor,D.Goodstein,A.Kuo,S.Minovitsky,R.Nikitin,R.A.Ohm,R.Otillar,A.Poliakov,I.Ratnere,R.Riley,T.Smirnova,D.Rokhsar,and I.Dubchak,Nucleic Acids Res.,2011 0:gkr947v1-gkr947.
[0334] Vogel,Microbiol.Genet.Bull.13:42-43,1956.
[0335] Wisconsin Genetics Software Package(Genetics Computer Group,Madison,WI)
[0336] Youngman et al.,Proc.Natl.Acad.Sci.USA 80:2305-2309,1983.
Claims
1. A modified Trichoderma sp. cell derived from a parent cell, the modified cell comprising a polynucleotide sequence encoding a variant LOV protein as shown in SEQ ID NO: 4, wherein when fermented under the same conditions, the modified cell comprises an increased protein productivity phenotype relative to the parent cell.
2. The modified cell of claim 1, comprising a polynucleotide encoding a protein of interest.
3. The modified cell of claim 1, comprising a polynucleotide construct encoding the NIK1 protein of SEQ ID NO:
19.
4. The modified cell of any one of claims 1-3, comprising at least one genetic modification that deletes, disrupts or reduces the expression / production of a protein selected from the group consisting of SSB7, MPG1 SFB3, SEB1, CRZ1, TSP2 and / or GAS1.
5. The modified cell of any one of claims 1-4, wherein the Trichoderma species is Trichoderma reesei.
6. The modified cell of claim 1, wherein the parent Trichoderma sp. cell comprises a polynucleotide sequence encoding a native LOV protein as shown in SEQ ID NO:
2.
7. A vector comprising a polynucleotide encoding the variant LOV protein as shown in SEQ ID NO:
4.
8. A polynucleotide encoding the variant LOV protein as shown in SEQ ID NO:
4.
9. A mutant Trichoderma strain derived from a parent strain, wherein the mutant strain comprises a gene encoding a LOV variant protein as shown in SEQ ID NO:4, wherein the mutant strain comprises an increased protein productivity phenotype relative to the parent strain. 10 . The mutant strain according to claim 9 , comprising a polynucleotide construct encoding the NIK1 protein of SEQ ID NO:
19.
11. The mutant strain of claim 9 or claim 10, comprising a genetic modification that deletes, destroys or reduces the expression / production of a gene encoding at least one protein selected from the group consisting of SSB7, MPG1 SFB3, SEB1, CRZ1, TSP2 and GAS1.
12. A method for constructing a modified Trichoderma sp. cell comprising a protein productivity-enhanced phenotype, the method comprising: (a) obtaining a parent Trichoderma sp. cell and introducing into the cell a polynucleotide construct encoding a LOV variant protein as shown in SEQ ID NO:4, and (b) isolating the modified cells of step (a), wherein the modified cell comprises an increased protein productivity phenotype relative to the parent cell.
13. A method for constructing a modified Trichoderma sp. cell comprising a protein productivity-enhanced phenotype, the method comprising: (a) obtaining a parental cell comprising a wild-type lov gene, wherein the lov gene encodes the LOV protein of SEQ ID NO: 2, (b) modifying the parent cell of step (a) to produce a modified cell comprising a gene encoding a LOV variant protein as shown in SEQ ID NO: 4, and (c) isolating the modified cells of step (b), wherein the modified cell comprises an increased protein productivity phenotype relative to the parent cell.
